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1 Summary 
The topic of this PhD work is to search the critical concentration of starch based 
disintegrant applying percolation theory and F-CAD (Formulation-Computer Aided Design) in 
order to design a pharmaceutical tablet formulation for a low water soluble drug. Critical 
concentration of maize starch (MS) for a ternary mefenamic acid (MA) tablet formulation with 
respect to a minimum disintegration time is investigated. Additionally implemented 
application of F-CAD to compute the disintegration time of MA tablet formulation is presented. 
This topic is related to push forward the idea of Quality by Design (QbD) of FDA (Food and 
Drug Administration) / EMEA (European Medicines Agency) / PMDA (Pharmaceuticals and 
Medical Devices Agency) and the exploration of the design space according to ICH 
(International Conference of Harmonization) Q8. 
The results of this work shows that the application of percolation theory is not limited to 
binary tablet formulation. The critical concentration of MS described by the renormalized MS 
concentration, MS/(MS+MA) applying the renormalization technique is always equal 0.198 
(dimensionless). Moreover the critical concentration of MS is optimized using the spline 
approximation with the dataNESIA software. It is leading to a minimum disintegration time at 
0.206, dimensionless, renormalized, which is very close to the experimental value of 0.198. 
According to the percolation theory, a minimum disintegration time corresponds to the 
formation of a continuous water-conducting cluster through the entire tablet. The critical 
volume fraction of an ‘infinite cluster’ that water can diffuse through the entire MA tablets are 
calculated with taking into account for the geometrical considerations between MS and MA 
particles based on random close packed (RCP) spheres system. The critical volume fraction 
of MS is calculated by the multiplication of critical concentration of MS and the solid fraction 
of MA tablets; which is within the range of 0.16 ± 0.01 (v/v). It is concluded that the critical 
volume fraction for three dimensional lattices is equal to 0.16 ± 0.01 (v/v); which is useful for 
the calculation of the critical concentration of starch based disintegrant in order to design the 
pharmaceutical tablet formulation based on scientific approach proposed by ICH Q8 
guidance. 
In addition, the disintegration behavior in the neighborhood of the percolation threshold is 
explained mathematically by the basic equation of the percolation theory, yielding a critical 
exponent q equal to 0.28 ± 0.06 (Quality of fit: r2 = 0.84). This value is close to the critical 
exponent for three dimensional lattices (q = 0.4). Thus, it is important, within a planned 
experimental design to optimize the disintegrant to take into account the percolation theory. 
However it has to be kept in mind that the determination of the percolation threshold and 
critical exponent does not give an answer about the absolute value of the disintegration time. 
Dissolution Simulation (DS) module, which is the one of F-CAD based on cellular automata 
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algorithm is used to simulate the disintegration time of a MA tablet. Disintegration time of 
tablet is assumed as the time elapsed till the water is detected at the geometric center of the 
virtual tablet. Comparison of experimental disintegration time of MA tablet and computed 
specific time point for water to reach the geometric center of the tablet by using F-CAD 
software has been carried out and shown an acceptable correlation (Correlation coefficient: r 
= 0.81). The detailed evaluation of the data shows that there is still a need for optimization of 
F-CAD for the calculation of the disintegration time in order to achieve a similar or the same 
performance like in the prediction of the dissolution profile of a tablet formulation. It is 
concluded that F-CAD software is the only software so far, which is capable of computing the 
disintegration time of tablets. The software has a great potential to be improved and to be not 
only used for the safe prediction of the dissolution profile of a tablet formulation but also for a 
safe prediction of the disintegration time. Thus, such a software is one of the tools for the 
substitution of laboratory experiments for the purpose of the design and development of new 
pharmaceutical solid dosage forms. The replacement of expensive laboratory experiments by 
in-silico experiments is an important issue to reduce development costs and to comply with 
the requirements of ICH Q8 exploring the design space with response surface methodology. 
The results of this thesis show in addition that the application of percolation theory is a must 
in order to detect percolation thresholds. It is important to know the response surfaces close 
to the percolation threshold of sensitive tablet properties such as the disintegration time to 
get information about the robustness of the selected formulation. In this context one has to 
put the question forward if the application of percolation theory should be an integral part of 
the guidelines of ICH Q8 exploring the formulation design space. 
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2 Introduction 
For the pharmaceutical formulation design and process development, the scientific 
understanding of those attributes that influence their quality should be provided while taking 
into account for quality by design (QbD) in International Conference on Harmonization (ICH) 
guidance Q8 (R2) [1]. The use of scientific approaches for the understanding of quality 
attributes, such as statistical design of experiment (DOE), response surface methodology 
(RSM), optimization modeling, multivariate data analysis and chemometrics in combination 
with the knowledge management system is required. 
Pharmaceutical formulations for solid dosage forms are complex and heterogeneous 
disordered particular system, i.e., multi-particulate and multi-component. Topological 
modeling is necessary to be taken into account for a geometrical description. Percolation 
theory is, in fact, one of the suitable topological modeling tools to predict and simulate the 
geometric phase transitions in complex system, such as a tablet formulation. Thus, 
percolation theory allows finding the regions where the system undergoes the geometrical 
phase transition. It happens at critical concentration of the components where a component 
percolates (percolation threshold). In terms of tablet formulation design, such regions are 
usually linked to external values of properties such as water uptake, disintegration time, and 
dissolution rate. 
Nowadays, because of the advance of combinatorial chemistry and high throughput 
screening, the number of poorly water soluble drug candidates has increased tremendously. 
More than 40% of newly discovered drugs are poorly water soluble. It has to be kept in mind 
that up to now there is no universal science-based formulation design for low water soluble 
drugs. In many cases disintegration is a limiting factor on the dissolution process of tablets. 
Disintegrant is used to aid the disintegration of tablets. Determination of the critical 
concentration of disintegrant is an important parameter for a tablet formulation design, 
especially for low water soluble drugs. Therefore, several research groups have reported the 
critical concentration of disintegrant that is required to achieve the minimum disintegration 
time [2-7]. In our laboratory, the percolation theory has been applied to determine the critical 
concentration of disintegrant in binary tablets [8-12]. However the further investigation is 
needed to determine the critical concentration of disintegrant not only for binary tablets but 
also for multicomponent tablets in order to design a pharmaceutical tablet formulation based 
on the scientific approach. 
Mefenamic acid (MA) is used as a model substance of a low water soluble drug. Fifteen 
types of granules and tablets are prepared at different loading volume of MA (0-74.1% v/v) in 
exchange of lactose (LA) (7.7-90.9% v/v) as a filler and maize starch (MS) (8.5-30.3% v/v) as 
a disintegrant corresponding to a truly ternary tablet formulation. In order to guarantee a 
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quality of a tablet formulation, however, it is not sufficient to evaluate to look only at one 
important characteristic such as the disintegration time, because other tablet properties need 
to fulfill the necessary requirements as well. In this respect, it has to be kept in mind that an 
optimization of disintegration time may jeopardize other important tablet properties such as 
the tensile strength. Thus, it is a prerequisite to study at least at the same time the weight, 
diameter, thickness, and hardness of a tablet. The weight, diameter, and thickness of tablets 
together with the measurement of apparent density of granules determine the porosity of the 
tablets. In order to get the more scientific understanding of the tablet characteristics, near 
infrared (NIR) imaging technology has been applied to visualize the components distribution 
on the tablet surface. 
The tablet quality is not only influenced by its materials [13-19] but also by tableting process 
parameters [20-22] when compressed. For an optimal formulation design, it would be 
desirable to manufacture the tablets on an industrial rotary tableting machine. However, 
because of the lack of a large amount of a drug substance at the earlier formulation design 
and development phases, these experiments are not possible. For this reason, the 
PressterTM [23] equipment, which needs only a small amount of powder material, was used to 
simulate mechanically a rotary tableting machine. 
Finding the rule for pharmaceutical tablet formulation design is necessary from the 
development cost and scientific approach point of view. Critical concentration of MS for a 
ternary MA tablet formulation with respect to a minimum disintegration time and the critical 
exponent of the disintegration behavior based on the percolation theory are discussed. 
Additionally implemented application of F-CAD to compute the disintegration time of MA 
tablet formulation is presented in this thesis. 
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3 Theoretical Introduction 
3.1 Formulation design for solid dosage forms 
3.1.1 The selection of pharmaceutical dosage form 
On the basis of the information about the target profile, clinical indication and pre-
formulation study, for example solubility, water-octanol partition coefficient, pKa, and stability 
in solution and in solid state of the new chemical entity (NCE), the dosage form for NCEs 
would be selected as oral dosage forms, parenteral dosage forms, topical dosage forms and 
so on. 
NCEs are rarely administrated alone and are almost always given as a pharmaceutical 
dosage forms. The oral route is the one most frequently used for drug administration and 
tablets are the most common pharmaceutical dosage forms today. Tablets are popular for 
several reasons. First the patient's point of view, tablets are convenient to handle because 
they are portable and easy to be administered. Second the cost of manufacturing, packaging 
and shipping is relatively low from manufacture's point of view. The third point is that tablet 
formulation enables high dose of active substances to design smaller than capsule 
formulation containing granules or powder as well as granules or powder themselves. 
The most important is however the fourth point, that solid dosage forms such as tablets, 
capsules etc. show a much higher physical and chemical stability than any other dosage 
form especially if compared with liquid formulations. 
3.1.2 Definition of low water soluble drug 
Nowadays, because of the advance of combinatorial chemistry and high throughput 
screening, the number of poorly water soluble drug candidates has increased tremendously. 
More than 40% of newly discovered drugs are poorly water soluble. The solubility in gastro-
intestinal fluids of a drug is an important factor affecting its bioavailability. Solid drugs 
administered orally for systemic activity must be dissolved in the gastro-intestinal fluids prior 
to their absorption site. European Pharmacopoeia (Ph. Eur.) 7.0 categorizes the solubility 
from the view point of milliliters of solvent required for dissolving 1 g of solute referred to a 
temperature between 15°C and 25°C. If 1 g of solid drug requires more than 10,000 mL, this 
drug is classed as practically insoluble (Table 1) [24]. 
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Table 1   European Pharmacopoeia (Ph. Eur.) 7.0 descriptive terms of solubility [24] 
Descriptive Term Approximate volume of solvent in milliliters
per gram of solute 
Very soluble less than 1   
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1,000 
Very slightly soluble From 1,000 to 10,000 
Practically insoluble more than   10,000 
 
On the other hand, the solubility for a classification in the Biopharmaceutics Classification 
System (BCS) is defined by FDA in 2000 (Table 2) [25]. Drugs are defined as highly soluble 
when the highest dose strength is soluble in 250 mL or less of an aqueous media over a pH-
range of 1.0-7.5. Drugs are defined as highly permeable when the extent of absorption is 
determined to be 90% or more of an administered dose based on a mass balance 
determination or in comparison to an intravenous dose. According to the FDA, the 
permeability class can be determined by humans, animal models (e.g. rat), in-vitro 
permeation studies with human or animal excised tissue or the use of cultured cell models 
(e.g. Caco-2 cells). 
 
Table 2   Biopharmaceutics Classification System (BCS) 
Solubility / Permeability High Low 
High Class I Class III 
Low Class II Class IV 
 
3.1.3 Advantages of granulation process 
The formulation designing and development for low water soluble drugs aiming to improve 
the dissolution behavior and thus bioavailability with common approaches is desirable for the 
pharmaceutical industry to shorten time to market. One common approach is granulation, 
which has several advantages, such as improved wettability and in vitro dissolution behavior 
of active ingredient [26], and improved flowability and compaction properties [27] of the 
whole formulation. 
Granulation methods can be divided into wet granulation, which is use a granulation liquid 
during its process, and dry granulation in which no granulation liquid is used. This dry 
granulation is used for the active pharmaceutical ingredients which are sensitive to water. 
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3.1.4 Principle of wet granulation 
Wet granulation process is that liquid is added to the powder mixture and will be distributed 
and then powder is agglomerated at the certain amount of liquid [28, 29]. Formation of 
granules results from a process classically defined by different states of saturation of liquid-
bound particles (Figure 1) [30, 31]. These wet bridges are only temporary states during wet 
granulation. However they are a prerequisite for the formation of solid bridges formed by 
adhesive in the presence of liquid or by materials that dissolve in the granulation liquid. 
Otherwise powder will be obtained after drying process. 
 Pendular state 
Empty space between particles is partly filled with binding liquid, which forms 
concave films between the particles. This state corresponds to the nucleation phase 
when nuclei are formed from isolated particles, which when wetted by the binding 
liquid form between particles by pendular linkage. 
 Funicular state 
With increasing the quantity of liquid, the liquid bridges (concave films) coalesce. 
However, air is still present in the empty space. Drying this phase, the nuclei formed 
grow via two mechanisms; 
- Isolated particles adhere to a nucleus by a pendular linkage 
- Two nuclei collide and form a large nucleus 
At the end of this stage many small granules of ranging sizes are obtained. 
 Capillary state 
The binding liquid totally fills the empty space between the particles, which are held 
together by the capillary suction at the liquid-air interface at the surface of the 
granules. This stage corresponds to further accretion; 
- The largest granules break up and recombine with small particles 
- Two granules coalesce 
- Small particles combine selectively 
- Particles adhere to large granules 
 Droplet state 
Continued wetting of particles can result in particles are suspended in the binding 
liquid. This must be totally avoided to obtain granules. On the other hand, this will be 
important for the process of granulation by spray drying of a suspension. 
Theoretical Introduction 
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prior to granulation
Pendular state
 
Figure 1.   The difference states of saturation of liquid-bound particles. 
 
3.1.5 Method of wet granulation 
Wet granulation process mainly divided into using a high-speed granulation or a fluidized 
bed granulation. Critical factor in wet granulation is the amount of granulation liquid used to 
get the prerequisite size of granules. There are many reports describing how to detect the 
end point of wet granulation. The way to detect the end point of high-speed granulation is to 
measure the power consumption of impeller [32, 33, 34], to measure the granules particle 
size by CCD [35] camera and acoustic measurement [36]. The same approach has been 
investigated to measure the particle size by CCD camera [34] and acoustic signal detected 
by sensor as shown in Figure 2 [37] for the fluidized bed granulation. 
 
 
Figure 2.   Sensor in fluidized bed granulator [37]. 
(1) Condenser microphone, (2) Fuse, (3) Platelet, (4) Cable, (5) Potting, 
(6) Container 
 
The advantage to use a fluidized bed granulator over high-speed granulator is that a mixing, 
granulation and drying are performed in one unit as well as operators are in safe side by 
  Theoretical Introduction 
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closed unit [38]. On the other hand, disadvantage to use a fluidized bed granulator over high-
speed granulator is that there are a lot of parameter affecting granules characteristics related 
to apparatus, process and product [39]. 
This complexity leads to the problems when this process is scaled up. Leuenberger has 
proposed the quasi-continuous granulation process by using Glatt® MulticellTM which consists 
of a horizontal high-speed granulator and three fluidized bed granulator to avoid scale up 
problem as currently trended [40, 41]. 
When compared with high-speed granulation, granules manufactured by fluidized bed 
granulator shows superior compressibility and less granules hardness due to the porous with 
small bulk density [42]. It is necessary to use the fluidized bed granulator if tablet includes 
the component which leads to cracking and capping tendency such as mefenamic acid (MA) 
[43]. 
3.1.6 Flowability of powder or granules 
There are many pharmaceutical manufacturing processes that require powder or granules 
to be moved from one location to another location. This is achieved by many kind of ways 
such as to use gravity force, mechanical feeding, pneumatic transfer and fluidization air. The 
flowability of powers or granules is a critical parameter in the production site of 
pharmaceutical dosage forms. In common, flowability can be evaluated by measurements of 
bulk density. Bulk density is a simple test developed to evaluate the flowability by comparing 
the poured density and tapped density of a powder or granules. 
A useful empirical index is given by Carr (Equation 1) [44]. 
 
Carr’s index (%) = 
 
100
tapped
bulktapped


                                                             Equation (1) 
where tapped is tapped density (g/cm3), bulk: bulk density (g/cm3). 
 
This index can be interpreted in Table 3. 
 
Table 3   Carr’s index as an indication of powder flow 
Carr’s index (%) Type of flow 
5 - 15 Excellent 
12 - 16 Good 
18 - 21 Fair to passable 
23 - 35 Poor 
33 - 38 Very poor 
> 40 Extremely poor 
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A similar index has been introduced by Hausner (Equation 2) [45]. 
 
Hausner ratio = 
bulk
tapped


                                                                                       Equation (2) 
where tapped is tapped density (g/cm3), bulk: bulk density (g/cm3). 
 
This index can be interpreted in Table 4. 
 
Table 4   Hausner ratio as an indication of powder flow 
Hausner ratio Type of flow 
< 1.25 Powder flows like granules 
1.25 - 1.5 Powder is of intermediate nature 
> 1.5 Powder is cohesive 
 
3.1.7 Tablet formulation design and development 
Tablets are the most common pharmaceutical dosage form today as described before. 
Pharmaceutical dosage forms compose both active pharmaceutical ingredients (API) and 
inactive ingredient so called excipients. The information on the compression properties of the 
API is extremely useful. Thus, if the API is high dose and it has plastic deformation, the 
chosen excipients should be brittle (e.g. lactose). If the drug is brittle or elastic, the excipients 
should be plastic, (e.g. microcrystalline cellulose). When the compression force is increased 
to the particles, deformation (particles change of form) will occur. If the deformation 
disappears completely (it means return to original shape) when the stress is released, it is an 
elastic deformation. A deformation that does not completely disappear after release of the 
stress is a plastic deformation. A characteristic for brittle material is the fact the plastic 
deformation is followed by a breaking of the materials. The deformation is dependent on the 
properties of the particles. 
Especially a disintegrant is added to most tablet formulations and very critical to facilitate 
disintegrating tablet into small particles in order to increase the surface area of API when 
tablet is exposed to the gastrointestinal fluids. Therefore, the appropriate type and amount of 
disintegrant is in many cases the critical factor to determine the tablet quality, although 
particle size, particle shape and packing geometry of disintegrant in a tablet has to be taken 
into account. 
The optimal selection of disintegrant is an important step, which needs a lot of laboratory 
experiments for the tablet formulation design based on the formulator's expertise and 
experience. 
  Theoretical Introduction 
  11 
3.1.7.1 Classification of disintegrant 
Main properties for a good disintegrant were pointed out [46]. 
 Strong hydrophilicity (to set up the continuous hydrophilic network in a tablet) 
 Weak hydrosolubility 
 Weak mucilaginous behavior in contact with water 
 Good flowability and good compressibility 
From the above mentioned point of view, disintegrants can be divided into mainly four 
groups: the native starches, modified starches, cross-linked polyvinylpyrrolidone, cellulose 
and modified cellulose [46]. 
 Native starches 
Native starches are potato, maize and rice starches. The typical concentration range 
of starch in a tablet is up to 15% w/w. Starch particles can swell when it contacts with 
water and facilitate disintegration by particle-particle reputation. 
 Modified starches 
Sodium carboxymethyl starch (Primojel®, Explotab®) are developed as a high-
swelling disintegrants which are included in a tablet at relatively low concentration, 
typically 1-5% w/w. According to the carboxymethylation and cross-linkage, the starch 
can be improved swelling capacity more or less up to a certain point.  
Partly pregelatinized starch (StaRX 1500®) is a maize starch physically modified by 
heating with/without pressure in the presence of water. Flowability and compressibility 
is improved in comparison with starch. 
 Cross-linked polyvinylpyrrolidone 
Because of its high molecular weight and cross-linked structure, this 
polyvinylpyrrolidone is insoluble in water but it is highly hydrophilic. It can absorb 
more than 50% of its own weight in water. Two kinds of Cross-linked 
polyvinylpyrrolidone (Polyplasdone XL®, Kollidon CL®) are available on the market. 
 Cellulose and Modified cellulose 
Croscarmellose sodium (Ac-Di-Sol®), Carmellose calcium (ECG-505®), Carmellose 
(NS300®), Low-substituted hydroxypropylcellulose (L-HPC®) are representatives. Due 
to their origin from the pulp of woody plant, their structure is fibrous. This fibrous 
structure is highly hydrophilic because of the numerous hydroxyl groups that allow for 
fast suction of water. 
3.1.7.2 Mechanism of tablet disintegration 
Several mechanisms of disintegration are suggested, such as swelling of disintegrants, 
disintegrant deformation recovery, wicking water into the pore between particles, reputation 
to break up the particle-particle bonding in tablet and exothermic wetting reaction [47]. 
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No simply theory was satisfactorily applied to all disintegrant process, however the four 
principle mechanisms are accepted as shown in Figure 3 [47]. However it is an universally 
fact that fast water diffusion into the tablet is necessity. 
 Swelling 
Particles swell and break up the tablet from within; swelling sets up localized 
stresses that spread throughout the tablet. 
 Deformation 
Particles swell to pre-compression size and break up the tablet. 
 Wicking 
Water is pulled into pores by the disintegrant and reduces the physical bonding 
forces between particles. 
 Repulsion 
Water is drawn into pores, and particles repulse each other because of the resulting 
electrical force. 
 
 
Figure 3.   Mechanisms of action for tablet disintegrants. 
 
3.1.7.3 Factors influencing tablet quality 
The tablet quality is not only influenced by the particle size [18], particle shape [13], 
crystallinity [14], particle deformation properties [15-17] and its composition [19] but also by 
tableting conditions, such as compression force [21] and tableting speed [20, 22]. Therefore 
constant and robust tablet quality is still a challenge for the pharmaceutical industry. 
There are two types of tablet press in common use in pharmaceutical company. One is the 
single station eccentric press and another is multi station rotary tablet press. There are both 
mainly three steps of tablet compression on a rotary press. 
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 Die filling 
The die is filled by powder or granules when the lower punch is in the lowest 
position, then the lower punch is moved to its target position and excess material is 
scraped off. The placement of powder or granules in the die depends on its flowability, 
on its physical properties (size, shape, density, etc.) and on the flow conditions 
(hopper shape, centrifugation forces, machine vibration itself). 
 Tablet formation (Pre-compression and Main-compression) 
The upper punch descends and enters the die and the powder or granules are 
compressed until a tablet is formed. The lower punch can be stationary or move 
upwards in the die. After maximum applied force the upper punch leaves the powder 
or granules. Tanino et al. reported that pre-compression helps in removal of 
entrapped air and improves bonding between particles during the compaction phase 
[48]. 
 Tablet ejection and Take off 
The lower punch rises and the tablet is removed by a pushing device. A lubricant 
plays important role to minimize the stress between tablet and punch and/or die 
during ejection. 
Because of the lack of a large amount of API at the earlier formulation design and 
development phase, the experiments to use the multi station rotary tablet press are not 
possible. What the most difference between the multi station rotary tablet press and the 
single station eccentric tablet press is the dwell time during the tableting. The dwell time of 
the single station eccentric press is much longer as compared with the multi station rotary 
tablet. The difference of dwell time is the possibility to change the packing geometry related 
to the porosity of tablet. 
3.1.7.4 Introduction of PressterTM 
Tablet properties such as a hardness, disintegration or dissolution behavior may change 
when a tableting process is changed from one machine to another. In short, important 
parameters such as porosity, pore size and pore volume depending on compression force 
and compression speed [49-51] are related to the dwell time (Figure 4). As mentioned above, 
it would be desirable to manufacture the tablets on a rotary tableting machine for industrial 
use for an optimal formulation designing. However, because of the lack of a large amount of 
API at the earlier formulation designing and development phase, these experiments are not 
possible. For this reason, the MCC (Metropolitan Computing Corporation) PressterTM 
equipment [23], which needs only a small amount of powder material, was used to simulate 
mechanically a rotary tableting machine. An excellent concept of PressterTM is a linear-type 
rotary tableting machine replicator so that one single station tablet press (Figure 5) with 
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standard tooling can move with high speed by mimicking the industrial multi station rotary 
tablet press. PressterTM is instrumented with Linear Variable Differential Transformers 
(LVDT) for upper and lower punch displacement measurement. Moreover strain gauges were 
installed for force measurement during pre-compression and main compression, for die wall 
expansion measurement with instrumented die, for ejection force and for tablet take-off force. 
The scale up factors PressterTM are helpful for designing a tablet formulation, but cannot 
completely simulate an industrial multi station rotary due to the following differences:  
 Feeding protocol 
 Distance between pre-compression roll and main compression roll 
 Turret heating effect and Centrifugal force effect due to linear construction 
 Vibration effects 
 
B
C
A
A : Contact time
B : Dwell time
C : Upper punch movement
 
Figure 4.   Schematic explanations of contact time and dwell time. 
 
 
Figure 5.   Schematic of PressterTM. 
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3.2 Near infrared (NIR) imaging 
3.2.1 Introduction of NIR and NIR imaging 
The US Food and Drug Administration (FDA) strongly advocated that Process Analytical 
Technology (PAT) initiative [52] has promoted the idea of improving the quality of the 
pharmaceutical products by deeper understanding processes involved in drug manufacturing. 
The ultimate goal is to achieve quality by design of pharmaceutical dosage forms.  
Spectroscopic techniques such as near infrared (NIR) are nowadays used for process 
control and quality assurance due to the advantage of their rapid, nondestructive analysis. 
NIR spectrophotometer was listed in European pharmacopoeia as a general monograph in 
1997. It has a wide variety of applications for both chemical and physical analysis according 
to the European pharmacopoeia (Ph. Eur.), for example identification of active substances 
and excipients [53]. 
NIR spectral range extends from about 780 nm to about 2500 nm (from about 12800 cm-1 
to about 4000 cm-1). NIR spectra are dominated by C-H, N-H, O-H and S-H overtone 
resonances and combination of fundamental vibrational modes [53]. In NIR spectroscopy, 
only one spectrum per sample is obtained. However the technique to acquire several 
thousand spectra per one measurement has developed in order to provide spatial 
information of a data cube which is hyperspectral NIR imaging as shown in Figure 6. 
 
Hyperspectral image (data cube)
NIR spectrum Single wavelength image
High intensity
Low intensity
 
Figure 6.   Diagram of hyperspectral NIR imaging [54]. 
 
3.2.2 Application of NIR imaging in tablet formulation design 
There are various parameters established well in the modern pharmacopeia in order to 
assess the tablet quality such as its appearance, weight, thickness, hardness (tensile 
strength), friability, moisture, assay, content uniformity, disintegration time, dissolution 
profiles. On the other hand, NIR imaging in pharmaceuticals has nowadays developed as an 
analytical tool for pharmaceutical formulation [55] insight in order to get more scientific 
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understanding. NIR imaging provides spatial, chemical, structural, and functional information. 
The increased understanding at the micro-scale such as the particle size of the APIs in the 
formulation and how it distributes relative to other components can improve the formulation 
characteristics. Several applications of NIR imaging in pharmaceuticals during formulation 
development have been reported. For example, it was used to show the content uniformity 
problems attributed to the large API agglomeration in powder blend [56], to detect the 
chemical composition of granules [57], it was also applied to monitor the coating thickness of 
tablets [58]. However a few physical characteristics related to the tablet quality have been 
reported. It was to assess the density or porosity in tablet when the compression force was 
different [59], to demonstrate the disintegrant cluster size increased with increasing the 
compression force in order to explain the alteration of the product dissolution [60]. In this 
thesis, NIR imaging technology has applied to visualize multi component distribution on the 
tablet surface according to the loading volume of MA in order to get the more scientific 
understanding of the tablet characteristics. 
3.3 Response surface methodology 
3.3.1 Response Surface Methodology (RSM) and Design of Experiment (DOE) 
Response surface methodology (RSM) is one of the useful approaches for selecting the 
optimum pharmaceutical formulation design on the basis of the experimental data. 
Leuenberger and Guitard published in 1978 from Sandoz Pharmaceutical Research Labs the 
article “Drug Delivery Systems for Patient Compliance” [61] with a DOE using central 
composite design (CCD) manufactured 27 batches, i.e. an orthogonal factorial design with 
five factors, which was able to show a response surface with a quadratic polynomial equation. 
DOE is recommended by FDA [1, 52] as mentioned by Ajaz Hussain, at that time deputy 
director, who visited the laboratories of the Institute of Pharmaceutical Technology at the 
University of Basel in 2004 with Helen Winkle [62], the actual Director of FDA’s Office of 
Pharmaceutical Science of the Center for Drug Evaluation and Research (CDER). DOE 
should replace “Trial and Error” experiments in the Pharmaceutical R & D laboratories 
(Figure 7) [62]. The DOE using central composite designs (CCD) has the intrinsic property to 
check the response surface if a minimum or a maximum or a saddle is part of the surface 
(Figure 8 and 9) [61]. DOE can be also used for drug-excipient compatibility studies [63]. 
Thus, RSM and DOE enable to explore the behavior of a formulation by changing the 
concentration of the excipients, drug substance and process parameters according to today’s 
requirements of ICH Q8 [1, 52, 64, 65]. 
Such a study can be called a “sensitivity analysis” of the robustness of a formulation to be 
marketed. A “sensitivity analysis” is in general an integral part of an F-CAD (Formulation-
Computer Aided Design, see section 3.6.2) in-silico analysis searching the most robust tablet 
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formulation for a specific drug dissolution profile in different buffer media (pH 1.2, pH 6.8, pH 
7.2 etc.). In the present study, F-CAD was tentatively applied to give an estimate for the 
tablet disintegration time as the drug substance has extremely low water solubility. 
 
Figure 7.   Knowledge pyramid (according to Dr. A. Hussain, FDA) [62] 
 
 
 
Figure 8.   Hardness of a tablet as a function of compression force and concentration of 
corn starch [61]. 
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Figure 9.   Hardness of a tablet as a function of compression force and concentration of 
magnesium stearate [61]. 
 
Table 5   Three Dimensions on the Critical Path [64, 65] 
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Table 6   Working in Three Dimensions on the Critical Path [64, 65] 
(C) H Leuenberger University of Basel Slid
FDA Whitepaper March 2004 
Three Dimensions of the Critical Path
 
 
The simplest 2n design with two factors A, B including the Yates scheme is described below 
in Table 7 and Figure 10. Table 7 and Figure 10 are part of Leuenberger’s lecture in 
University of Basel for undergraduate students. Yates scheme of a 22 Design with A = 
amount of maize starch (MS, lower level -: 10 mg, upper level +: 15 mg) and B = 
compressional force (lower level -: 6 kN, upper level +: 8 kN). Please note that this is a 
“tutorial” and the Results included in Table 7 corresponding to the percentage of drug release 
after 1 hour. According to the Yates scheme, the effect of 2A, 2B and the interaction 2AB 
between the factor A and B can be quantified. This is the most important point of using 
factorial designs that it is possible to check for possible interactions and possible to quantify 
such interactions. The evaluation of the above very simple design leads to the result below: 
 
Table 7   2n design with n = two factors A, B including the Yates scheme 
Yates A B AB Results 
(1) - - + 82 
a + - - 82 
b - + - 78 
ab + + + 95 
Σ 2A 2B 2AB T/4 
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Figure 10.   Graphical representation of the evaluation of the above Yates scheme with the 
factor A = amount of maize starch (Menge Maisstärke) A0 and A1 and the factor 
B (Presskraft) with the compressional force p0 and p1. 
 
It is possible to write down the mathematical model F(x1, x2) of a 2n design with n = 2 
factors (variable x1 corresponding to factor A, variable x2 corresponding to factor B) as 
follows: 
 
21122211021 ),( xxbxbxbbxxF                                                                       Equation (3) 
 
Equation 3 is called “summarizing equation” of the 22 design with b0 = T/4, b1 = A/2, b2 = 
B/2 and b12 = AB/2 (interaction term). The values of A, B and AB can be simply calculated 
using the Yates scheme of Table 7. Thus, e.g. the value of 2A is equal to the sum of the 
column of the Results taking care of the plus or minus signs in the Table 7: 
i.e. - 82% + 82% - 78% + 95% = 17% = 2A, - 82% - 82% + 78% + 95% = 9% = 2B 
+ 82% - 82% - 78% + 95% = 17% = 2AB 
i.e. b0 = T/4 = 84.25%, b1 = 4.25%, b2 = 2.25%, b12 = 4.25% 
leading to the Equation 4: 
  )%..(),,( 21 dissolvedeixxF  
        2121 %25.4%25.2%25.4%25.84 xxxx                                                   Equation (4) 
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With the values of x1, x2 according to the coded values in Table 7, i.e. +1 or -1, evidently, 
the summarizing equation is able to reproduce the result of each experiment [(1), a, b, ab] in 
Table 7. Due to the fact that the 2n design is orthogonal, the value of the coefficients b1, b2, 
and b12 can be compared directly. Please note that the value of b12, i.e. the interaction term 
AB has the same magnitude, in fact identical in this case, as the effect of the factor A, which 
is described with the value b1. Thus, it is important in pharmaceutical sciences that 
interactions can play an important role, which can be detected with DOE but can be missed 
by just doing a conventional experiment with changing only one factor a time and keeping 
constant the remaining factors. However it has to be kept in mind in Table 7 that no 
replicates of the experiments have been performed, i.e. the mathematical model F(x1, x2) is a 
first approximation of the reality. 
The simplest central composite design (CCD) with just two factors A, B (Table 8) is called a 
“3 x 3” design which leads to the following nine experiments with the following factor levels; -
1 (lower level), +1 (upper level), 0 (mean of the levels +1, -1) and the level α, which depends 
whether the central composite design (CCD) is orthogonal or rotatable. In case of two factors 
A, B, the value of α is equal to 1.414 for a rotatable and equal to 1 for an orthogonal CCD. 
 
Table 8   Central composite design (CCD) with just two factors A, B 
Factor Experiment No. 
A B 
1 -1 -1 
2 +1 -1 
3 -1 +1 
4 +1 +1 
5 -α 0 
6 +α 0 
7 0 -α 
8 0 +α 
9 0 0 
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It is also possible to write down for a CCD as a summarizing equation (Equation 5), which 
looks as follows for the factors A and B using the transformed variables z: 
 
2222111112122211021 ),( zazazazazaaxxF                                               Equation (5) 
 
With z1 = x1 - m(x1), z2 = x2 - m(x2), z12 = x1 x2 - m(x1 x2), z11 = x12 – m(x12), z22 = x22 - m(x22), 
m(x) means mean value of x, the value of x is again coded, i.e. -α, -1, 0, +1, -α in case of the 
orthogonal CCD α is equal to 1. For the purpose that the coefficients a0, a1, a11, a12 and a22 
are orthogonal, the mean of x12 and x22 needs to be equal to (4 + 2α)/9 = m(x12) = m(x22) [66]. 
It is important to keep in mind that the summarizing equation (Equation 5) of a CCD is only 
able in a second approximation of the reality to yield as a response surface, which shows a 
minimum a saddle point or a maximum. If the grid of the lattice is too large, it is possible that 
a minimum surface may not be detected (see second CCD in section 6.11.3). 
Please note that a formulation which contains three components such as maize starch (MS), 
lactose (LA) and mefenamic acid (MA) can be easily reduced to a two component system 
consisting of MS (disintegrant) and of the ratio LA/MA, which is the ratio of the hydrophilic 
filler LA and the hydrophobic drug substance MA. Thus, it is possible to construct the 
simplest CCD with two factors MS and LA/MA (see section 6.11.3). 
For the evaluation of the CCDs in section 6.11.3, it is possible to use the software Design-
Expert 7®, which is able to calculate the r2 values among others, i.e. the percentage of the 
data, which are explained by the mathematical model and is able to plot the corresponding 
response surface in three dimensions. 
3.3.2 dataNESIA software 
Conventional RSM typically uses a linear regression model and a partial least square 
regression (PLSR) model and a quadratic polynomial equation approximation to generate a 
response surface from experimental data. However the prediction of pharmaceutical 
responses based on the conventional RSM is often resulting in poor estimations for optimum 
pharmaceutical formulation design because pharmaceutical formulations for solid dosage 
forms are complex and heterogeneous disordered particles systems, which have non-linear 
characteristics [67, 68]. Artificial neural network (ANN) may be used for pharmaceutical 
formulation design which has non-linear characteristics; however it is laborious and time-
consuming task to find the optimum modeling [68]. 
Yamatake & Co., LTD. and Takayama [67, 68] have developed new RSM incorporating 
multivariate spline interpolation (RSM-S) represented by a spline approximation (biharmonic 
spline or thin-plate spline) [68-70], in order to interpolate the experimental data distributed at 
random in a multidimensional space for the response surface generation. 
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3.3.3 Multivariate spline interpolation 
Multivariate spline interpolation has been effectively used as a tool to interpolate altimeter 
data in the field of geophysics. The basic concept of multivariate spline interpolation involves 
a boundary element method which can be considered as the transformation equation of 
elasticity such as a thin elastic beam shown in Figure 11 as an example [67]. 
 
 
Figure 11.   A function y that passes through the data points y1 located at x1 is found by 
applying point forces α1 to a thin elastic beam [67]. 
 
The experimental data were also considered as the variations at each point, and the spline 
approximation gives the solution of transformation equation of elasticity to be minimized the 
elastic strain energy (Equation 6) [70]. 
 
   dsxfE s 22                                                                                               Equation (6) 
where ∇2 is the Laplacean and ∫s ds is the integration over all ranges 
 
Green functions were used for solving Equation 6. The biharmonic spline used in this thesis 
was expressed in Equation 7 [70]. 
 
 in
i
i dgy 


1
                                                                                                     Equation (7) 
where n is the number of data points, di is the standardized Euclidian distance between x 
corresponding to number i data point and the optimal x, g(di) is the green function whose 
variables are di. 
 
The definition of this function is changed by the dimensions of the input variable (x). αi is a 
coefficient calculated by a linear matrix operation. 
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3.4 Percolation theory 
3.4.1 Principles of percolation theory 
Pharmaceutical formulations for solid dosage forms are complex and heterogeneous 
disordered particular systems. Topological modeling is necessary to be taken into an account 
for a geometrical description. Percolation theory is, in fact, one of the suitable topological 
modeling tools to predict and simulate the geometric phase transitions in complex systems, 
such as a tablet formulation [8]. Geometrical phase transitions are independent of physical 
and chemical properties of the components. In other word, the geometrical phase transitions 
have universally happened and this facilitates the modeling. Thus, percolation theory allows 
finding the regions where the system undergoes the geometrical phase transition. It happens 
at critical concentration of the components where a component percolates (percolation 
threshold, pc) and where the system property often shows a great change, which is called as 
catastrophic change in this thesis. In terms of tablet formulation design, such regions usually 
linked to external value of properties such as water uptake, disintegration time, and 
dissolution rate. It is essential to note that a percolation threshold is a volumetric (not a 
mass) ratio (v/v) of the components from the view point of geometrical aspect. Percolation 
theory itself is an instrument of probability theory. 
This introduction to percolation theory cannot be exhaustive and follows the lines given by 
Stauffer and Aharony. For detail understanding, it is recommended to read “Introduction to 
percolation theory” [71]. There is the excellent Japanese translated textbook by Odagiri [72]. 
Percolation theory deals with the number and properties of those clusters [71]. The 
underlying idea of cluster and its percolation is to see a system as composed of subunits 
(site) that are distributed randomly on a two dimensional lattice. In the simplest case, the 
lattice is square (Figure 12) and the squares are either occupied or empty. There are mainly 
two kinds of cluster types, site cluster and bond cluster. 
 Site cluster 
Some sites are occupied with a certain probability (ps) and some are empty with 
certain probability (1 - ps). Site clusters are defined as groups of neighboring occupied 
site shown as groups of circles in Figure 12. 
 Bond cluster 
Each sites of the lattice are occupied, and some of them are connected though line 
shown as circles connected by thick bars in Figure 12. 
Gray colored circles represent the percolated cluster in the square lattice [73]. 
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Figure 12.   Groups of circles are defined as a site clusters and circles connected by thick 
bars are defined bond clusters. Gray colored circles represent the percolated 
cluster in the square lattice [73]. 
 
For the tablet formulation design, we assume that the packing geometry of particles in the 
tablet is more important to consider than the collision of particle each other. Thus, this thesis 
deals almost with site percolation. 
In site percolation, the formation of clusters is a function of the occupation probability (p) of 
the lattice chosen. Figure 13 and 14 show that a site percolation phenomenon with an 
occupation probability (p) below and above the percolation threshold (pcs = 0.592746) in 
square lattice respectively [71]. The percolation threshold is defined as an occupation 
probability (p) where for the first time a percolating cluster is formed. Below percolation 
threshold (pcs), only isolated clusters exist. However near the percolation threshold (pcs) an 
‘infinite cluster’ is formed spanning the whole lattice from left to right and from top to bottom. 
This ‘infinite cluster’ leads to the catastrophic change in the system. 
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Figure 13.   Square lattice (site percolation, i.e. random occupation of lattice sites) with an 
occupation probability (p) below the critical concentration, i.e. percolation 
threshold (pc). No 'infinite cluster' is formed. Two finite clusters are shown [71]. 
 
 
Figure 14.   Square lattice (site percolation) with an occupation probability (p) below the 
critical concentration, i.e. percolation threshold (pcs). An 'infinite cluster' 
percolates the system [71]. 
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There are other lattices not only in two dimensions but also in three or more [71]. Examples 
of two dimensions (a, b) and three dimensions (c-g) lattices are shown in Figure 15. 
 
(a) Honeycomb (b) Triangular (c) Bethe (d) Simple cubic  
 
(f) Face centered cubic (FCC)(e) Body centered cubic (BCC)
(g) Hexagonal close packing (h) Diamond  
 
Figure15.   Examples of two dimensions (a, b) and three dimensions (c-g) lattices. 
(a) Honeycomb, (b) Triangular, (c) Bethe (coordination number z=3) 
(d) Simple cubic, (e) Body centered cubic (BCC), (f) Face centered cubic (FCC) 
(g) Hexagonal close packing, (h) Diamond 
 
The main postulate of percolation theory is the probability (p) of forming an infinite cluster 
spanning through the infinite lattice is the Kolmogorov's zero-one law [11]. As a small 
isolated cluster grows, there will be a point, when for the first time it spans through the 
system. The percolation threshold (pc) is a so-called as an infinite cluster through the system. 
At or near the percolation threshold (pc), catastrophic change in the system occurs. A typical 
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example of catastrophic change can be seen in a particle mixture containing black particles 
which are electrically conductive, and white particles which are insulators and are no 
electrical conductivity. It is known that site percolation threshold on simple cubic lattice is 
0.311608 [71]. If black/white particles system described in Figure 16 is composed to a tablet, 
the tablet became electrically conductive just at the percolation threshold [74, 75].  
 
 
Figure 16.   A typical example of catastrophic changes in the system at or near the 
percolation threshold (pcs = 0.311608). 
where p is probability of black powder, I is electrical conductivity [75]. 
 
The percolation threshold (pc) is a quantity for a system depending on the lattice type, the 
dimension of the system and on the type of percolation [71] (non-universality). 
Three dimensions lattices should be considered for the designing of pharmaceutical tablets. 
Critical parameters on three dimensional lattices are summarized in Table 9. For three 
dimensional lattices face-centered cubic (FCC), body-centered cubic (BCC), simple cubic 
(SC), diamond and random close packed (RCP), the threshold values have been calculated 
[76, 77, 78, 79]. The threshold values for bond (pcb) and site (pcs) percolation are different 
from the different lattices. 
However, the key point is that critical volume fraction (c) is nearly constant, varying by just 
a few percent from three dimensions lattice to lattice. The critical volume fraction (c) is close 
to 0.16 (v/v) for the three dimensions as shown in Table 9, and is close to 0.45 (v/v) for the 
two dimensions (universality) [77]. 
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The relationship between c and pcs is expressed in Equation 8. 
 
csc pf                                                                                                           Equation (8) 
where f is the filling factor of the lattice which represents the solid fraction of the volume, 
and pcs is site percolation threshold (= critical concentration). 
 
Table 9   Critical parameters on three dimensional lattices 
Lattice pcb pcs Coordination
Number, z 
Filling 
Factor, f 
z pcb f pcs 
(c) 
FCC 0.119[77] 0.198[77] 12[77] 0.7405[76, 77] 1.43 0.15 
BCC 0.179[77] 0.245[77] 8[77] 0.6802[76, 77] 1.43 0.17 
SC 0.247[77] 0.311[77] 6[77] 0.5236[76, 77] 1.48 0.16 
Diamond 0.388[77] 0.428[77] 4[77] 0.3401[76, 77] 1.55 0.15 
RCP  0.27[77] 6[78] 0.64[79] 1.62 0.17 
Average     1.5 ± 0.1 0.16 ± 0.01
 
Thus, critical volume fraction (c = 0.16 ± 0.01, v/v) can predict the site percolation 
threshold. Experiments were carried out to determine the conductivity threshold composed of 
metallic and insulating spheres for random close packed (RCP). In this context, it is important 
to realize, that the two components in the focus (metallic and insulating spheres) need to 
have different properties to show the percolation effect such as an electric conductivity or 
being an insulator. The critical volume fraction of metric sphere was in rough agreement with 
0.16 (v/v) [80, 81, 82]. In addition, Wu and McLachalan [83] studied that critical volume 
fraction (c) of graphite/boron-nitride composite was 0.15 (v/v), which was also close to 0.16 
(v/v). 
3.4.2 Application of percolation theory in pharmaceutical area 
Percolation theory was introduced to design the pharmaceutical formulation by 
Leuenberger [8, 84] for not only solid dosage form but also liquid dosage form [85]. Caraballo 
et al. has applied the percolation theory to explain the influence of main formulation factors 
on drug release from hydroxypropyl methylcellulose (HPMC) matrix system [86]. 
The percolation threshold of the water uptake [9, 10, 12], disintegration time [9-12] and 
intrinsic dissolution rate [9, 10] of binary tablets has been investigated in our laboratory. In 
case of disintegration time, the critical concentration of disintegrant for which the 
disintegration time reaches a minimum was observed. Remarkably, the critical volume 
fraction of continuous water conducting cluster as the value of 16 (% v/v) was concluded to 
show the critical concentration of disintegrant in the random close packed (RCP) spherical 
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binary tablets [11, 12]. In order to design a pharmaceutical tablet formulation, the critical 
concentration of disintegrant should be determined not only for binary tablets but also for 
multicomponent tablets. Caraballo and Leuenberger et al. reported that the existence of a 
‘combined percolation threshold’ of sum of all the hydrophilic substance was at ca. 35% v/v 
in the ternary controlled release matrix system containing KCl, polyvinylpyrrolidone cross-
linked (PVP-CL) and Eudragit RS-PM [87]. No one, however, has reported experimentally 
the location of critical concentration of disintegrant for a ternary immediate release 
pharmaceutical tablet formulation. 
3.5 Percolation threshold of disintegration time with particle packing 
geometry considerations 
Disintegration process of tablet in case of non-fibrous disintegrant, e.g. maize starch (MS) 
is under the following conditions; 
 A disintegrant with swelling properties is present in the tablet. 
 The disintegrant itself is able to conduct water. 
 There is porous structure in the tablet which can conduct water by wicking. 
Further theoretical postulates are based on the following assumptions regarding to the 
particle packing geometry; 
 Pharmaceutical tablet is a random close packed (RCP) spheres system. 
 Drug and disintegrant particles are assumed to be spherical. 
 Particle size distributions are narrow but can be different for each component. 
 There is no significant deformation of drug particle within the compact. 
3.5.1 Random close packed (RCP) spheres system 
Particles in a pharmaceutical tablet are arranged in a disordered close packing. It is 
assumed that spherical compacted particles can be placed at random and are in close 
contact with their direct neighbors. Such a system is named random close packed (RCP) 
spheres system. Macro observations of spheres in RCP reveals that the most stable, 
probable and smallest local packing of spheres are hexagonal close packing or simple cubic 
close packing highlighted by red in Figure 17. 
 
  Theoretical Introduction 
  31 
 
Figure 17.   Two dimensional view of a RCP spheres system with example (circle in red) of 
the two smallest and most probable local packing: hexagonal close packing or 
simple cubic close packing [12]. 
 
It has to be pointed out that a RCP system can be composed of different size. A few local 
hexagonal close packing or simple cubic close packing can still be identified in a tablet. 
3.5.2 Sphere caging and non-caging concept in case of binary RCP system 
When RCP system is the binary system composed of small and bigger spheres, it is easier 
to understand the concept of the sphere caging and non-caging concept [11, 12]. If the size 
difference between two spheres is large enough, small sphere (red) can be caged by bigger 
spheres (black) in a hexagonal close packing (Figure 18 (a)-1 or (a)-2). If a small sphere 
(red) is too large for being caged but is still below the critical caging size, this sphere (red) 
can be caged by bigger spheres (black) as a part of body centered cubic (BCC) (Figure 18 
(b)). Above this critical caging size, caging by black spares in simple cubic (SC) is not 
possible any more (Figure 18 (c)-1). The caging sphere (black) will be apart and caged 
sphere (red) will be closer each other (Figure 18 (c)-2). 
Thus sphere caging in RCP system can be distinguished as two classes. If the small 
spheres can be caged by bigger sphere in hexagonal close packing or simple cubic close 
packing, it is defined as case I. If not, it is defined as case II. 
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(a)-1 (a)-2 (b) (c)-1 (c)-2
Case I Case II
 
Figure 18.   Sphere caging and non-caging for RCP system [12]. 
 
The radius r of the small sphere (red) that can be caged by four other bigger spheres 
(black) of radius R in simple cubic (SC) can be calculated by Equation 9. 
 
 Rr 13                                                                                                       Equation (9) 
 
According to Equation 9, if the r/R ratio is less or equal to 0.732 it is defined as case I. If not, 
it is defined as case II. 
3.5.3 Sphere caging and non-caging concept for binary drug/disintegrant tablet 
When tablet is the binary system composed of spherical drug and disintegrant particles, it is 
easier to understand how to apply previous concept of the sphere caging and non-caging for 
binary RCP system into the pharmaceutical area. The case I and II described previously are 
applied to the caging of disintegrant particles by drug particles. If a disintegrant particles can 
be caged by drug particles as a part of body centered cubic (BCC) or simple cubic (SC), it is 
classified as case I. If a disintegrant particles is too large for being caged by drug particles as 
a part of body centered cubic (BCC), it is classified as case II. Thus, the drug particles will be 
apart and disintegrant particles will be closer each other, and it is possible to create an 
infinite cluster through a tablet depending on its probability. If r is the mean particle radius of 
disintegrant and R is the mean particle radius of drugs, particle caging in a tablet in case of 
binary system of spherical drug/disintegrant is classified by Equation 10 and 11. 
 
Case I:  Rr 13                                                                                          Equation (10) 
 
Case II: r >  R13                                                                                          Equation (11) 
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3.5.4 Water diffusion network for binary spherical drug/disintegrant tablet 
When tablet is the binary system composed of spherical drug and disintegrant particles, it is 
easier to understand how the water can diffuse into the previous concept of sphere caging 
and non-caging in binary RCP system. Because it is important to consider and classify the 
water diffusion networks in a tablet according to the percolation theory. According to the 
percolation theory, a minimum disintegration time corresponds to the formation of a 
continuous water-conducting cluster through the entire tablet. The water can diffuse between 
drug particles by wicking (porous network) and through disintegrant particles (solid network). 
In case I (left in Figure 19), the network created by disintegrant particles consists of the 
porous network between drug particles caging disintegrant particles and disintegrant solid 
network. 
In case II (right in Figure 19), porosity and disintegrant represent two independent networks 
for the water diffusion. However the porous network is assumed to be occupied by swelling 
of big disintegrant particle. 
 
 
Figure 19.   Left: Water diffusion porous networks in case I, Right: Water diffusion solid 
networks in case II. 
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3.5.5 Calculation of critical concentration of disintegrant for spherical binary 
drug/disintegrant tablet 
As shown in Table 9, critical volume fraction (c) of an ‘infinite cluster’ for random close 
packing (RCP) spheres system is equal to 0.16 ± 0.01 (v/v). This value can be used for the 
calculation of the critical concentration of spherical disintegrant in order to achieve the 
minimum disintegration time of tablet. 
When tablet is the binary spherical drug and disintegrant particles system, it is easier to 
understand how to calculate the critical concentration of spherical disintegrant based on the 
sphere caging and non-caging concept. 
In the case I, the critical volume fraction of continuous water-conducting cluster involves 
both critical volume fraction of disintegrant and critical volume fraction of pore. If it is 
assumed that the porosity is constituted only by the pore between drug particles and pore is 
spherical, the critical concentration of the disintegrant (v/v) can be calculated by Equation 12. 
 
     11,, disporecdiscc X  

 


 1
c
disX                                                                                               Equation (12) 
where Xdis is the critical concentration of disintegrant in powder mixture (v/v), c is the 
critical volume fraction of an ‘infinite cluster’ 0.16 ± 0.01 (v/v), c,dis is the critical volume 
fraction of disintegrant (v/v), c,pore is the critical volume fraction of pore (v/v) and ε is the 
tablet porosity (v/v). 
 
In case II, porosity and disintegrant represent two independent networks for the water 
diffusion. However the porous network is assumed to be occupied by swelling of big 
disintegrant particles. The water diffusion through disintegrant particles is only taken into 
account. Critical concentration of the disintegrant (v/v) can be calculated by Equation 13. 
 
   1, disdiscc X  


 1
,disc
disX                                                                                                        Equation (13) 
where Xdis is the critical concentration of disintegrant in powder mixture (v/v), c is the 
critical volume fraction of an ‘infinite cluster’ 0.16 ± 0.01 (v/v), c,dis is the critical volume 
fraction of disintegrant (v/v) and ε is the tablet porosity (v/v). 
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Equation 14 represents a generalized model to determine the critical concentration of 
spherical disintegrant for drug/disintegrant RCP sphere system. 
 

 


1
c ;   if  13 
R
r
    CaseI  
disX                                                                                                                Equation (14) 


1
c              if  
R
r
> 13      CaseII  
where Xdis is the critical concentration of disintegrant in powder mixture (v/v), c is 0.16 ± 
0.01 (v/v) and ε is the tablet porosity (v/v). 
3.5.6 Critical exponent 
Various system properties (X) related to the cluster is decided by the occupation probability 
(p) of cluster in the system. System property related to the occupation probability (p) of 
cluster can be described by the fundamental power law of percolation theory [74, 84] in 
Equation 15. 
 
 qcppSX                                                                                                   Equation (15) 
where X is a system’s property, S is a proportionally constant (= scaling factor), p is an 
occupation probability, pc is a critical concentration (= percolation threshold), q is a critical 
exponent, close to the percolation threshold. Please note that the difference (p - pc) in 
Equation 15 is considered as an absolute value, i. e. there are no negative value. 
 
It is important to know that the critical exponent only depends on the dimension of the 
system but neither on lattice type nor on percolation type (universality). For example, the 
strength of the infinite cluster for probability p above the percolation threshold can be 
described by Equation 16, the mean cluster size below the percolation threshold can be 
described by Equation 17. System properties (X) and the corresponding critical exponents for 
two dimensions (d = 2) and three dimensions (d = 3) are summarized in Table 10.  
For this reason there are two approaches to predict the region of catastrophic change in 
complex system by Equation 15 either to find the percolation threshold or to find the critical 
exponents of the system. 
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Table 10   System properties X and the corresponding critical exponents for d = 2 and d = 3 
[71, 73] 
Critical exponent System property (X) Equation Exponent
d = 2 d = 3 
Strength of infinite cluster |p-pc|β (16) β 5/36 0.4 
Mean finite cluster size |p-pc|-γ (17) γ 43/18 1.8 
Correlation length |p-pc|-ν (18) ν 4/3 0.9 
Cluster number density |p-pc|2-α (19) α -2/3 -0.6 
 
3.5.7 Fractal nature of infinite cluster near percolation threshold 
Figure 20 and 21 show an infinite cluster at the percolation threshold in two dimensions [74, 
88] and three dimensions [89, 90] respectively. The infinite cluster at the percolation 
threshold exhibits a self-similar structure, which is a prerequisite to define a fractal dimension. 
The fractal nature of a system is related to a certain scale length, which corresponds to the 
correlation length ξ [74]. The fractal geometry introduced by Mandelbrot [91] was applied to 
quantify the complexity of internal pore structure in a matrix type controlled release system 
[92, 93]. 
The cluster mass Mξ in the volume ξd is proportional to ξdf by definition with df the fractal 
dimension. A lattice of linear size L contain (L/ξ)d such volumes. Thus the total mass M∞ of 
such a lattice is proportional to ξdf  (L/ξ)d. The strength (P) of the infinite cluster is proportional 
to M∞/Ld. Thus the following relationship holds (Equation 20) [74]; 
 
)()( dfdc
ddf
d ppL
MP                                                                         Equation (20) 
 
The critical exponent of the strength (P) of the infinite cluster is equal to β. Thus the fractal 
dimension of the infinite cluster df can be calculated as follows for d = 2 and d = 3 (Equation 
21): 
 
 / dd f                                                                                                    Equation (21) 
where β and ν are indicated in Table 10, which are universal. 
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Figure 20.   The infinite cluster at the percolation threshold exhibits a self-similar structure, 
i.e. has a fractal dimension df = d - (β/ν) = 91/48 for d =2 [74, 88]. 
 
 
Figure 21.   An idealized three dimensional network of a pore system (Menger sponge) with 
the fractal dimension of d = 2.72 [89, 90]. 
3.6 F-CAD 
3.6.1 Goal of in-silico pharmaceutical formulation design 
The guideline published by the FDA (2004) [52] concerning the PAT-initiative presents a 
framework with two components: 
 Set of scientific principles and tools supporting innovation． 
 Strategy for regulatory implementation that will accommodate innovation.  
The goal of FDA’s PAT initiative is to achieve scientifically based decisions, i.e. to design 
the quality of the product and not to “test-in” the quality by eliminating the bad items at the 
end of the production creating waste of time and money [62]. The PAT-initiative is however a 
recommendation to the pharmaceutical industry and not a compulsory regulation. In this 
sense, FDA promotes as well the use of better manufacturing toolkit, in particular IT tools as 
below; “Scientists involved in reviewing medical devices at FDA report an urgent need for 
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predictive software to model the human effects of design changes for rapidly evolving 
devices. We believe that such software may be attainable with a concentrated effort, by 
assembling currently available data and identifying existing data gaps” in the "Challenge and 
Opportunity on the Critical Path to New Medical Products, FDA" [65]. For this software high 
performance computer system is necessary. But today, high performance computer systems 
that incorporate advanced hardware and software are commercially available, allowing 
scientists to simulate the formulation design, process development and its scale-up. The 
application of in-silico design and testing of solid dosage form is an innovative tool for 
fulfilling the requirements of PAT and the Quality by Design Initiative of FDA [94]. 
3.6.2 F-CAD capability for the pharmaceutical formulation design 
F-CAD developed by CINCAP GmbH [95] is a first principle approach using as software 
based on Cellular Automata (see section 3.6.4) in three dimensional mapping of the diffusion 
equation in order to predict the dissolution profile of the drug substance and is capable of 
detecting percolation thresholds [94] in complex formulations. Thus, F-CAD is based on 
physical laws and has among others the following capabilities [94, 96]: 
 Interpret experimentally measured data by providing the underlying physical models. 
 Propose laboratory experiments that may confirm unexpected theoretical predictions. 
 Cut down substantially the cost of laboratory work, based on a trial and error 
approach by giving valuable feedback to the experimentalists, which laboratory tests 
should be done for validation purposes. 
 In case of complex pharmaceutical formulations: F-CAD is able to establish 
intellectual property rights by providing results for drug delivery systems that have not 
yet been tested experimentally. 
Last but not least in the framework of perspectives [97]: 
 Replace in future laboratory experiments in case that the accuracy of numerical 
computations based on a first principle approach is better than that of experiments, 
which is of special relevance in case of biological, pharmaceutical and medical 
experiments, where the variability is intrinsically high [98]. 
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3.6.3 F-CAD software applications 
F-CAD software has three main parts: tablet geometry designer (TGD), process simulation 
(PS), and 3-D rendering, analysis and playback (RAP) module [99]. Tablet geometry 
designer (TGD) is specially focused on the pharmaceutical tablet design [100]. 
 Disintegrant Optimization (DO) 
This module calculates the critical concentration of disintegrant for a tablet 
formulation based on the percolation theory. The percolation threshold of the 
disintegration time is strongly dependent on the physical properties of the 
components. Thus it can be estimated on the basis of geometrics and physical 
consideration only. 
Required information for calculation is; 
- Volume of tablet 
- Weight of tablet 
- Mean particle size of the components 
- True densities of the components 
 Dissolution Simulation (DS) 
Cellular automate algorism is used to simulate tablet dissolution. Tablet to dissolve 
in-silico must be previously designed by Tablet Designer (TD) module and Particle 
Arrangement and Compaction (PAC) module.  The release profile of the API is 
calculated for each time point in accordance to initial setting value of individual 
component. 
 Tablet Designer (TD) 
This module serves to design tablet pattern and to transform it into a discrete 3D 
virtual tablet. The shape of a tablet is not limited to classical ovals or circles but also 
complex geometry. 
 Particle Arrangement and Compaction (PAC) 
The arrangement of particles and their location in a tablet can be designed by this 
module. Growth algorism is used to correspond to design the different size of 
particles.
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3.6.4 F-CAD core algorithm 
F-CAD is mainly based on percolation theory and special core algorithm cellular automata 
(CA) which is a sophisticated algorithm taken from nature phenomenon for the particulate 
formulation design. This is the reason why F-CAD cannot be compared to existing "Expert 
Systems" or "Artificial Neural Networks" [101, 102]. 
3.6.4.1 Cellular Automata 
Cellular automata were first introduced by Von Neuman and Ulam in 1940s. They had been 
looking for simple mathematical models describing phenomena in nature [103]. A cellular 
automaton (CA) is one of the topological optimization techniques [104], which can be applied 
in percolation theory. The underlying idea of cellular automata is to see a system as 
composed of subunits (square cell) that are discrete regularly on a lattice. In other words, a 
cellular automaton is a discrete model consisting of a regular domain of cells on a lattice. 
This scheme is very close to the concepts used in percolation theory. Each cell is 
characterized by a certain state, which typically consists of a finite domain. The system of 
cells evolves, in discrete time step, like simple automata which only know a simple recipe to 
compute their new state. New state of a cell at time t is a function of the states of a finite 
domain composed of target cell and its neighborhood at time t-1 according to the locale rules 
which depends only on the state of the cell and of the state of neighboring cell. The success 
of the application of CA in deferent domains is mostly related to its ability to take into account 
of the local interaction between spatial target cell and its neighborhood. 
Thus CA is considered to be suitable tool to calculate the percolation threshold in case of 
difficulty to calculate the percolation threshold by using percolation equation which can show 
the entire system's characteristic or behavior. 
3.6.4.2 Simplest examples of cellular automata application 
An attempt to use the cellular automata for designing the pharmaceutical formulation was 
conducted by CINCAP GmbH in 2007. Solid particle and liquid or porosity is represented of 
the individual cell controlled by certain rule which guides its state changes. For example, the 
solid particle cell is gradually changing its state after taking the liquid or porosity during the 
disintegration of tablet. The rate at which the solid particle takes liquid or porosity is governed 
by its solubility or volumetric change (swelling) rate constant which is unique for every API as 
well as for new excipient and to be determined through a calibration routine. It is important to 
note that the calibration routines for F-CAD are not necessary to be repeated every time the 
system used before [100]. 
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Now, one of the simplest one-dimensional cellular automata (CA) rule is introduced in order 
to understand CA and its application, which is a preferred procedure in nature. Elementary 
cellular automata have two possible states for each cell labeled 0 (white) and 1 (black) 
(Upper Figure 22). New state of a cell at time t will be formed depending on the states of a 
finite domain composed of target cell and its neighborhood at time t-1. Thus there are 2 x 2 x 
2 = 8 possible states for the target cell as well as its neighborhood. The rule defining the 
cellular automaton must specify the resulting state for each of these possibilities. Wolfram 
[103] proposed the rule of cellular automata. Below show graphically the rule 30 and 16 
updates of the system. The "00011110" is written 30 in binary. This is the reason why it is 
called rule 30. A picture of a seashell pattern (Lower Figure 22) resembles the system 
following the rule 30. Many other examples of similarity between CA based model and nature 
behavior were exciting [100]. It is suggested that CA based models are capable of imitating 
the behavior of nature system properties such as dissolution of tablet [100]. 
 
 
 
 
Figure 22.   Upper: pattern of one dimensional cellular automata generated with rule 30 
[103], Lower: natural pattern of a dangerous sea snail. 
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3.6.4.3 Application of cellular automata in pharmaceutical area 
Cellular automata (CA) has been used for the sustained drug release modeling from 
bioerodible polymer system by its surface erosion [105, 106], from non-erodible polymeric 
system [107], polymer membrane system [107] and from swelling polymer system which 
polymer absorbs water and creates the hydrogel layer [108]. In these models, each square 
cell is ruled to be updated two dimensionally. 
The handicap of two dimensional CA is considered that it is only able to show the 
percolation threshold for a two dimensional system. Kier et al. investigated a CA model for 
the dynamic two dimensional system (square lattice). In his report, the percolation threshold 
spanning the cluster entire system was observed at the range of 0.512 to 0.661 [109]. This 
was close to the site percolation threshold of square lattice, 0.592746, not for the three 
dimensional system. On the other hand, each cubic cell in F-CAD is ruled to be updated for 
three dimensional systems. F-CAD has more advantages to simulate the percolation 
threshold or dissolution profile such as a three dimensional tablet. However the rule of CA to 
simulate the drug release from three dimensional systems in F-CAD has not been disclosed 
yet. 
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4 Objectives 
The objective of this PhD work is to search the critical concentration of starch based 
disintegrant applying percolation theory and F-CAD (Formulation-Computer Aided Design) in 
order to design a pharmaceutical tablet formulation for a low water-soluble drug. For the 
pharmaceutical formulation design and process development, the use of scientific 
approaches for the understanding of quality attributes in combination with the knowledge 
management system are required for the purpose of quality by design (QbD) based on ICH 
Q8. 
Critical concentration of maize starch (MS) for a ternary mefenamic acid (MA) tablet 
formulation with respect to a minimum disintegration time is investigated. The critical volume 
fraction (c) for three dimensions investigated is equal to 0.16 ± 0.01 (v/v); which was 
demonstrated to predict the conductivity threshold in the area of the material sciences. In our 
laboratory, the critical volume fraction (c) for three dimensions (0.16 ± 0.01, v/v) has been 
investigated to calculate the critical concentration of non-fibrous disintegrant, StaRX1500® for 
the binary mixture of caffeine or paracetamol/StaRX1500® tablet [11, 12]. However the 
further investigation is needed to determine the critical concentration of non-fibrous 
disintegrant for not only binary tablets but also for pharmaceutical tablet formulation. No one, 
however, has reported experimentally the location of critical concentration of disintegrant for 
a ternary immediate release pharmaceutical tablet formulation. Percolation theory can lead to 
the percolation threshold and critical exponent of disintegrate behavior but it does not give an 
answer about the absolute value of the disintegration time. Thus, the Dissolution Simulation 
(DS) module which is part of F-CAD being based on a cellular automata (CA) approach is 
implemented to simulate the disintegration time of MA tablet. F-CAD is able to calculate, 
applying CA with the number n of updates, ti necessary till water is detected at the geometric 
center of the virtual tablet. Thus, it is possible to define a time t, i.e. the “time elapsed” till 
water molecules have reached the center of the tablet. In a very first approximation, the 
value of the calculated “time elapsed” can be considered as an estimate of the real 
disintegration time. However, it has to be kept in mind that “time unit” for the updating event 
has to be defined in an arbitrary, but reasonable way. In an earlier study (see PhD thesis of 
Krausbauer [12] and Figure 9 of the paper in SWISS PHARMA [96]), a reasonable guess 
was made for the updating “time unit” resulted in the fact that the real disintegration time 
occurred after the water is detected at the geometrical center of the virtual tablet. It is evident 
that there may be a link between the “time elapsed” to reach the geometrical center of the 
tablet and the disintegration process, which may be different for non-fibrous starch type 
disintegrants and for other types of disintegrants such as the “superdisintegrant” Ac-Di-Sol”. 
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Comparison of experimental disintegration time and computed specific time point for water 
to reach the geometric center of the tablet by using F-CAD software is useful to show the 
capability of F-CAD for a tablet formulation design in order to save money by replacing 
laboratory experiments. Thus, classical trial and error experiments can be avoided and only a 
fraction of laboratory experiments need to be made for the validation of the best in-silico 
formulations.
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5 Materials and Methods 
5.1 Materials 
Mefenamic acid (2-[(2,3-Dimethylphenyl)amino]benzoic acid, Figure 23), hereinafter MA, 
was purchased from Fluka Chemie GmbH, Lot No. 023K0927 (Buchs, Switzerland). Lactose 
monohydrate (LA) (Lot No. 083451, USP/EP; Pharma 200/15, Alpavit, Lauben/Allgaeu, 
Germany) and maize starch (MS) (Lot No. 41951073, USP/EP; Maisita 21.000-50, Agrana, 
Gmuend, Austria) were used in the formulation of the ternary system with hydroxypropyl 
cellulose (HPC SL) (Lot No. NCH-0911, EP/JP; HPC SL, Nippon soda, Tokyo, Japan) as a 
binder for the wet granulation process. Magnesium stearate (Mg-St) (Lot No. K2 41155, 
Actelion Pharma Schweiz AG, Allschwil, Switzerland) was used as a lubricant for tableting. 
 
 
Figure 23.   Chemical formula of mefenamic acid (MA) 
 
5.2 Physical properties of starting materials 
The physical properties of the above mentioned materials are compiled in Table 11. MA, LA, 
MS and Mg-St was used as API, filler, disintegrant and lubricant respectively. The shape of 
MA (Figure 24), LA (Figure 25), MS (Figure 26) and Mg-St (Figure 27) were examined by the 
Scanning Electron Microscope (SEM) using JSM-5310LV (JEOL, Tokyo, Japan, Figure 28) 
under the conditions described below; 
 Vacuum pressure：27 Pa (Low vacuum condition) 
 Accelerated voltage：15 kV 
 Current load：104 A 
 
Table 11   Physical properties of the starting materials 
 Mean diameter True density SSA, 
 (m) (g/cm3) (m2/g) 
MA 6.57 1.264 1.87 
LA 39.4 1.556 0.33 
MS 25.0 1.537 0.31 
Mg-St 4.15 1.088 20.2 
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Figure 24.   SEM of mefenamic acid (MA). 
 
 
Figure 25.   SEM of lactose monohydrate (LA). 
 
 
Figure 26.   SEM of maize starch (MS). 
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Figure 27.   SEM of magnesium stearate (Mg-St). 
 
 
Figure 28.   Scanning Electron Microscope (JSM-5310LV, JEOL, Tokyo, Japan). 
 
The mean diameter by volume of starting material was determined with a laser 
diffractometer (HEROS & LODOS, Sympatec, Clausthal-Zellerfeld, Germany, Figure 29) at 
500 mm focal length. The dispersing pressure was 0.2 MPa and the injector suction was 0.01 
MPa. The particle size distribution of MA, LA and MS are shown in Figure 30, 31 and 32 
respectively. The true density was measured by a helium pycnometer (AccuPyc 1330, 
Micromeritics, Norcross, GA, USA, Figure 33) at room temperature. The cell and expansion 
volume were 12.0563 cm3 and 8.4153 cm3, respectively. The equilibration rate was 0.01 
psig/min, i.e. 68.91 Pa/min. The specific surface area (SSA) was determined by nitrogen 
adsorption method using an automatic surface area analyzer (Gemini 2360, Micromeritics, 
Norcross, GA, USA, Figure 34). For this purpose, MA, LA, MS and Mg-St MA was dried for 1 
hour at 100 °C, LA for 1 hour at 80 °C, MS for 28 hours under vacuum at room temperature 
(MS) and Mg-St for 2 hours at 40 °C, respectively. The measurements were performed using 
a 6-point Brunauer-Emmett-Teller (BET) mode with nitrogen gas and a relative pressure 
range between 0.05 and 0.30. Data were calculated according to BET methods [110]. 
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Figure 29.   Laser diffractometer (HEROS & LODOS, Sympatec, Clausthal-Zellerfeld, 
Germany). 
 
 
Figure 30.   MA particle size distribution. 
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Figure 31.   LA particle size distribution. 
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Figure 32.   MS particle size distribution. 
 
 
Figure 33.   Pycnometer (AccuPyc 1330, Micromeritics, Norcross, GA, USA). 
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Figure 34.   Automatic surface area analyzer (Gemini 2360, Micromeritics, Norcross, GA, 
USA). 
 
5.3 Granulation 
Granulation was performed with 125 g batch per batch by fluidized bed granulator Mini-
Glatt (Glatt, Binzen, Germany, Figure 35). The starting compositions and quantity per batch 
for the granulation are shown in Table 12 and 13 respectively. The compositions are 
indicated by both % w/w, and % v/v. The composition of MA was increased by 10% w/w in 
exchange of LA/MS (7/3) as excipients from Granule A to H. The composition of MS was 
kept at 15% w/w, 21% w/w and 9% w/w from Granule I to K, L to M and N to O respectively. 
The HPC SL solution of 6% w/v was top-sprayed as a granulating binder. The content of 
HPC SL in the final granulate was kept at 3.5% (w/w) for all batches. The spraying rate of 
HPC SL solution was kept at 6.4-10.6 g/min (Sci-Q pump, 323U/D, Watson-Marlow Bredel 
Pumps, Falmouth, UK); the atomizing air pressure was kept at 0.04 MPa for all batches. The 
inlet air temperature was varied within 70-80 °C; the fluidization air pressure was varied 
within the range of 0.012-0.03 MPa. During the granulation, the product temperature and 
relative humidity in the powder bed were monitored using a hygrometer (HMI41/HMP42, 
VAISALA, Helsinki, Finland). Temperature and relative humidity (R.H.) were in the range of 
22.6-33.3 °C and 46.3-85.7% R.H., respectively. Granulation time was kept within the range 
of 753-1133 seconds. Drying was stopped when the product relative humidity (R.H.) was 
below 5.0%. 
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Figure 35.   Fluidized bed granulator Mini-Glatt (Glatt, Binzen, Germany). 
 
Table 12   Starting compositions for wet granulation 
 Composition (%) 
 MA LA MS 
 (w/w) (v/v) (w/w) (v/v) (w/w) (v/v) 
A   0   0 70 69.7 30 30.3 
B 10 12.0 63 61.4 27 26.6 
C 20 23.5 56 53.4 24 23.1 
D 30 34.5 49 45.7 21 19.8 
E 40 45.0 42 38.4 18 16.6 
F 50 55.1 35 31.3 15 13.6 
G 60 64.8 28 24.6 12 10.6 
H 70 74.1 21 18.1   9   7.8 
I   0   0 85 84.8 15 15.2 
J 30 34.5 55 51.3 15 14.2 
K 70 74.1 15 12.9 15 13.0 
L   0   0 79 78.8 21 21.2 
M 70 74.0   9   7.7 21 18.3 
N   0   0 91 90.9   9   9.1 
O 30 34.5 61 57.0   9   8.5 
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Table 13   Quantity per batch for granulation 
 Quantity per batch (g) 
 A B C D E F G H I J K L M N O 
MA 0 12.5 25.0 37.5 50.0 62.5 75.0 87.5 0 37.5 87.5 0 87.5 0 37.5
LA 87.5 78.75 70.0 61.25 52.5 43.75 35.0 26.25 106.25 68.75 18.75 98.75 11.25 113.75 76.25
MS 37.5 33.75 30.0 26.25 22.5 18.75 15.0 11.25 18.75 18.75 18.75 26.25 26.25 11.25 11.25
Subtotal 125.0 125.0 125.0 125.0 120.5 125.0 125.0 125.0 125.0 125.0 125.0 125.0 125.0 125.0 125.0
HPC SL 4.38 4.38 4.38 4.38 4.38 4.38 4.38 4.38 4.38 4.38 4.38 4.38 4.38 4.38 4.38
Total 129.4 129.4 129.4 129.4 129.4 129.4 129.4 129.4 129.4 129.4 129.4 129.4 129.4 129.4 129.4
Materials and Methods 
54 
5.4 Tableting 
For this study the resulting granules were fractionated in order to remove the fines (< 90 
m) and the fraction above 500 m. Thus ensembles of the particles with the size between 
90 m and 500 m were used for compression. They were mixed with 0.5% w/w of Mg-St in 
a Turbula mixer (Type T2A, Willy A. Bachofen, Basel, Switzerland, Figure 36) for 2 minutes 
and then compressed to a 416 mg (± 1.0%) tablets as described in Table 14. The mixtures 
were compressed to tablets by using a compaction simulator (PressterTM, Metropolitan 
Computing Corporation, East Hanover, NJ, Figure 37), mechanically simulating a high-speed 
industrial rotary tableting press, Korsch PH 336 at the turret speed of 35 rpm corresponding 
to the output capacity of 75,600 tablets per hour. The diameter of pre-compression roll and 
compression roll was identical with those of Korsch PH 336, which are 110 mm and 300 mm, 
respectively. The ejection angle was set to 7.6 °. Tablets were compressed at approximately 
7.0 kN (6.6-7.4 kN), 5.0 kN (4.7-5.3 kN) and 3.0 kN (2.7-3.3 kN) with the dwell time of 16.9 
ms using 10 mm flat-faced standard IPT B-tooling. Pre-compression force was kept between 
0.6-1.7 kN. The dwell time (ms) was calculated by Equation 22 [23]. 
 
Dwell  time
OCPCD
NSL

 
000,600,3
                                                                      Equation (22) 
where L is the diameter of the flat portion of the punch head (12.7 mm in the case of IPT, 
Industrial Pharmaceutical Technology, standard B tooling), NS is the number of stations , 
PCD is the pitch circle diameter of the turret and OC is the output capacity in tablets per 
hour. 
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Figure 36.   Turbula mixer (Type T2A, Willy A. Bachofen, Basel, Switzerland). 
 
 
Figure 37.   Compaction simulator (PressterTM, Metropolitan Computing Corporation, East 
Hanover, NJ) 
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Table 14   Tablet compositions 
 Quantity per tablet (mg) 
 A B C D E F G H I J K L M N O 
MA 0 40 80 120 160 200 240 280 0 120 280 0 280 0 120
LA 280 252 224 196 168 140 112 84 340 220 60 316 36 364 244
MS 120 108 96 84 72 60 48 36 60 60 60 84 84 36 36
HPC SL 14 14 14 14 14 14 14 14 14 14 14 14 14 14 14
Subtotal 414 414 414 414 414 414 414 414 414 414 414 414 414 414 414
Mg-St 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Total 416 416 416 416 416 416 416 416 416 416 416 416 416 416 416
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5.5 Granules characterization 
5.5.1 SEM 
The shape of granule A, D, F and H were examined by the Scanning Electron Microscope 
(SEM) using JSM-5310LV (JEOL, Tokyo, Japan) under the conditions described below; 
 Vacuum pressure：27 Pa (Low vacuum condition) 
 Accelerated voltage：15 kV 
 Current load：104 A 
5.5.2 Moisture determination 
Loss on drying of 1.5 g samples was measured at 80 °C for one hour using an infrared 
drying unit (LP 16, Mettler, Greifensee, Switzerland, Figure 38). 
 
 
Figure 38.   Infrared drying unit (LP 16, Mettler, Greifensee, Switzerland). 
 
5.5.3 Size distribution and Mean diameter 
The size distribution of granule was evaluated by sieve analysis method using the 710, 500, 
355, 250, 180, 125, and 90 m ISO-norm sieves. The sieves were vibrated at 50 Hz for 5 min 
by using a sieve shaker (Vibro, Retsch, Haan, Germany, Figure 39). The sieve load was 25.0 
g. The fraction remaining on each sieve was determined by weighing. The mean diameter 
was calculated as 50% in diameter by plotting the cumulative percentage oversize against 
sieve size on log-probability graph. 
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Figure 39.   Sieve shaker (Vibro, Retsch, Haan, Germany). 
 
5.5.4 Bulk, Tapped and Apparent density 
Bulk and tapped density was calculated as the ratio of the weight to the volume of granules 
poured into a glass cylinder without or with tapping using a Jolting volumeter (J. Engelsmann, 
Ludwigshafen/Rhein, Germany, Figure 40) at a tapping rate of 247 taps per minute for one 
minute. Apparent density of the granules (90-500 m) was measured using a pycnometer 
(AccuPyc 1330, Micromeritics, Norcross, GA, USA) with helium gas at room temperature. 
The cell and expansion volume were 12.0563 cm3 and 8.4153 cm3, respectively. The 
equilibration rate was 0.01 psig/min, i.e. 68.91 Pa/min. 
 
 
Figure 40.   Jolting volumeter (J. Engelsmann, Ludwigshafen/Rhein, Germany). 
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5.5.5 Intragranular pore volume 
Intrusion volume of mercury into the particle size fraction of granules (90-500 m) was 
determined using a mercury porosimeter (Poresizer 9320, Micromeritics, Norcross, GA, 
Figure 41) at different pressure ranging from 1.5 to 30,000 psia, i.e. from 10.34 kPa to 
206.73 MPa, corresponding to the pore diameters between 120 m and 6 nm. Equilibration 
time was 10 seconds at each pressure. The pore diameter corresponding to the intrusion 
volume of mercury under a certain pressure was calculated by Equation 23 using mercury 
porosimetry [111]. 
 
P
KD washburm
 cos4                                                                                     Equation (23) 
where D is the pore diameter (m), Kwashburn is the washburn constant, , γ is the surface 
tension of mercury (485 × 10-5 N/cm), θ is the contact angle (130°) and P (psia) is the 
pressure. 
 
The pore diameter less than 14 m is assumed to be an intragranular pore open to the 
surface [112]. 
 
 
Figure 41.   Mercury porosimeter (Poresizer 9320, Micromeritics, Norcross, GA). 
 
5.5.6 MA assay 
414 mg of the particle size fraction of granules (90-500 m) was accurately weighed in a 
volumetric flask. 30.0 mL of distilled water was added and shaken at the speed of 150 cycles 
per minute (cpm) in a water bath at 37 °C for 30 min. 0.1 N NaOH was added accurately until 
100.0 mL and filtered (HLC-DISK 13, 0.45 m, Kanto Chemical, Tokyo, Japan). The filtrate 
was diluted to the range of 8-20 g/mL as MA concentration with 0.1 N NaOH and measured 
by UV spectrophotometer (DU® 530, Beckman Coulter, Fullerton, CA, Figure 42) at 285 nm. 
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Figure 42.   UV spectrophotometer (DU® 530, Beckman Coulter, Fullerton, CA). 
 
5.6 Tablet characterization 
5.6.1 Hardness and tensile strength 
The hardness of six tablets was measured with a tablet tester (8M, Dr. Schleuniger 
Pharmatron, Solothurn, Switzerland, Figure 43). The tensile strength of each tablet was 
calculated by Equation 24 [113]. 
 
TD
HTS 
 
2
                                                                                                    Equation (24) 
where TS is the tensile strength (N/cm2), H is the hardness (N), D is the diameter (cm) 
and T is the thickness (cm) of a tablet, respectively. The diameters and thicknesses of the 
tablets were measured with a digital caliper (Figure 44). 
 
 
Figure 43.   Tablet tester (8M, Dr. Schleuniger Pharmatron, Solothurn, Switzerland). 
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Figure 44.   Digital caliper. 
 
5.6.2 Calculated Porosity 
The porosity of the tablets was calculated according to Equation 25 [112]. 
 
10011 


   V
M
                                                                                         Equation (25) 
where ε is the porosity (% v/v) of a tablet, M is the tablet weight (g), V is the tablet volume 
(cm3) and ρ is the apparent density of granules (g/cm3) used for tableting. 
 
5.6.3 NIR imaging 
One faces of each tablet were imaged by chemical imaging system (Sapphire, Malvern 
Instruments Ltd., UK, Figure 45). The instrument consists of a liquid crystal tunable filter 
(LCTF) for wavelength selection, and cooled indium antimony (InSb) focal plane array (FPA) 
detector with 256 × 320 pixels. The system includes an appropriate optics to preferentially 
capture diffusely reflected light from each specimen, while minimizing background specular 
reflection off polished mounting plate. Four tungsten source lamps illuminate the imaging 
target field. The NIR imaging data of the diffuse reflection spectra were collected 10 nm 
intervals in the 1200-2400 nm regions with 32 co-added scans at each wavelength point. The 
spatial resolution of NIR imaging data in this experiment was 40 m/pixel, so the field of view 
was 10.2 × 12.8 mm. The size of domain of each component which was defined as a group 
of each component were measured based on the pixel size. 
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Figure 45.   Chemical imaging system (Sapphire, Malvern Instruments Ltd., UK) [55]. 
 
5.6.4 Disintegration time 
The disintegration time of the triplets of the tablets was measured by using the SOTAX 
disintegration testing equipment (DT 2, Sotax, Allschwil/Basel, Switzerland, Figure 46) 
without disk. The medium consisting of 750 mL distilled water was kept at 37 ± 0.5 °C. The 
frequency of the basket-rack movement was kept at 30 cycles per minute. 
 
 
Figure 46.   Disintegration testing equipment (DT 2, Sotax, Allschwil/Basel, Switzerland). 
 
5.6.5 Pore size distribution, Median pore diameter and Porosity 
The pore diameter of tablet corresponding to the intrusion volume of mercury under a 
certain pressure was calculated by Equation 23 using a mercury porosimeter. The median 
pore diameter by volume was defined as the pore diameter at which 50% of the mercury 
volume intruded up to 30,000 psia (VHg,30,000psia) [114]. The compact volume of tablet and 
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porosity (%) were measured by Equation 26 and Equation 27 respectively [111]. Tablets 
before and after using a mercury porosimeter are pictured in Figure 47. 
 
psiaHgCELLSAMPLE VVV 25,                                                                                   Equation (26) 
1001 000,30, 







 
SAMPLE
psiaHgSAMPLE
V
VV
Porosity                                                   Equation (27) 
where VSAMPLE is the sample volume (mL), VCELL is the sample cell volume (mL), VHg,25psia is 
the mercury volume (mL) intruded up to 25 psia, i.e. 172.28 kPa. 
 
 
Figure 47.   Tablet before and after using a mercury porosimeter. 
 
5.7 Data Analysis 
5.7.1 Data treatment for NIR imaging 
Data were treated using chemical imaging software (ISys, Malvern Instruments Ltd., UK). 
That enables the simultaneous manipulation of 81,920 pixels from a single field of view. For 
imaging analyses, the second derivative spectra calculated from the original data before 
proceeding with further analyses were used. The concentration of the each component in 
tablet was estimated by using the partial least square regression (PLSR) technique. No 
concentration standards are required for this experiment, as the spectra of starting materials 
were taken for reference. 
5.7.2 Response surface methodology 
The response surface of the disintegration time of tablet as a function of MA volume (%, 
v/v) and maize starch volume (%, v/v), was established by dataNESIA software (Yamatake, 
Fujisawa, Japan). Given method is based on the spline approximation incorporating the 
multivariate interpolation. 
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5.7.3 Renormalization 
The current study is focused as ternary formulation: MA, LA, MS in order to establish the 
connectivity to the binary systems, the following renormalization leading to a dimension 
reduction was applied (Equation 28): 
 
MAMS
MS
MS XX
XX '                                                                                            Equation (28) 
where X’MS is a volumetric part of maize starch recalculated for a binary system, XMS, XMA 
are volumetric parts of maize starch and mefenamic acid, respectively. 
 
The renormalization is mainly a technique to map three dimensional data down to two 
dimensions. This dimension reduction is only possible and allowed due to the dominating 
effect of MA in the tablet for concentrations of MA >> 23.5 % (v/v), i.e. for concentrations, 
that exceed the percolation threshold of MA (pcMA). Thus, in practice it is important and 
prerequisite to look only at formulations with a high dose of MA, i.e. with an MA load larger 
than 20% (w/w). It has to be noted that proposed renormalization is independent on the 
nature of a third component in the mixture. However, there are limitations. Thus, the 
renormalization procedure should be applied with caution. 
Depending on the situation, a renormalization process is not an absolute necessity as the 
comparison between Figure 57 and 61 is documenting. Both figures show clearly the 
behavior of the disintegration time of tablets compressed at 7 kN and the existence of the 
percolation threshold. In case of Figure 57 as a function of the content of MA and in case of 
Figure 61 as a function of the renormalized concentration of MS/(MS+MA). Instead of the 
renormalization process mentioned above, an elegant solution for a reduction of one factor is 
to introduce a ratio for one of the factors. Thus, in the case of three components MS, LA and 
MA the reduction is as follows: factor A = MS and factor B= LA/MA. It is evident that the 
second and the third component should not have a similar function as the disintegrant, which 
is studied, i.e. the third as well as the second component should not show a swellability or 
showing a function in competition with the excipient studied. 
It has to be kept in mind that renormalization is possible if number of particles of third 
component is significantly less than of the particles of the other components in the mixture. In 
the present case this is guaranteed by high load of MA above the percolation threshold. 
Another limitation is that the particles of the third component should preferably have a non-
fibrous structure, i.e. should look in an ideal case like a sphere. In addition, it should be kept 
in mind that the majority of pharmaceutical formulations, which consist in reality of more than 
two components can be reduced to two component systems in a really straight-forward way. 
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It is often absolutely correct to do the following abstraction from a complex tablet formulation 
consisting of one single drug substance and e.g. seven other excipients. For the scientific 
formulator, it will be important, at which volume fraction the drug substance will percolate. 
Thus, it will be important to know the particle size distribution of the drug substance and the 
particle size distribution of all other excipients involved. In other words, the scientific 
formulator has reduced the complex, multi-component system to a simple binary system. The 
same procedure can be applied for any other component in the system such as the 
disintegrant. The system becomes more complicated if two different disintegrants are 
involved in a complex formulation. 
5.7.4 Assumption of disintegration time computed by F-CAD 
Disintegrant Optimization (DO) module of F-CAD currently is used to calculate the critical 
concentration of disintegrant in a tablet for a minimum disintegration time based on the 
percolation theory. F-CAD cannot calculate the disintegration time because the mechanical 
destructive force in disintegration testing [115] and/or the experimental method used in the 
laboratory for example, with disk or without disk is not able to be taken into account. 
In this PhD work, Dissolution Simulation (DS) module, which is the one of F-CAD are used 
to simulate the disintegration time of a MA tablet compressed at 7 kN which is assumed that 
the time elapsed till water is detected at the geometric center of the virtual tablet. 
5.7.5 F-CAD operation 
There are mainly three F-CAD operations [100] are required to compute the specific time 
the water is detected at the geometric center of the virtual tablet. 
 Three dimensional design of MA tablet in order to create the wall constraint by Tablet 
Designer (TD) module. 
 Packing the components of MA tablet into the hollow tablet by Particle Arrangement 
and Compaction (PAC) module. 
 Compute the specific time elapsed until the water is detected at the geometric center 
of the virtual tablet by Dissolution Simulation (DS) module. 
Materials and Methods 
66 
5.7.5.1 Tablet Designer (TD) operation 
Figure 48 shows the wall appearance of Tablet F (flat-face) compressed at 7 kN created by 
TD module. Inputted parameters for Tablet F compressed at 7 kN are described as a sample 
followings; 
 Number of Handles: 32 
 Smooth point: 5 
 Smooth (mm): 0 
 Circle, Radius (mm): 4.985 
 Flat portion, height (mm): 4.47 
 Elliptic Cap Radi. (mm): 4.985 
 
 
Figure 48.   Wall appearance of Tablet F compressed at 7 kN created by TD module of F-
CAD with permission from CINCAP GmbH. 
 
5.7.5.2 Particle Arrangement and Compaction (PAC) operation 
The second stage of F-CAD operation is an arrangement of MA granules and St-Mg and 
their location in a tablet created by TD module. Before that, tablet created by TD module has 
to be discretized in order to put the prerequisite number of three dimensional cells into it. In 
this study, the number of three dimensional cell inside of the tablet was 104 which size was 
96.15 m/cube side. 
In order to simulate that granules are arranged into tablet, the ‘Swiss cheese’ procedure 
developed by CINCAP GmbH was applied [100] because it is assumed that granulated 
particle should be grown until a specified or sized size at limited location in a tablet as 
competed with direct compressive tablet from powder mixture. 
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Figure 49 shows the top view of Tablet F (flat-face) compressed at 7 kN created by PAC 
module. The order the each component was arranged is described below; 
i. Grow LA 
ii. Grow MS 
iii. Distri. MA 
iv. Distri. HPC SL 
v. Distri  Mg-St 
vi. Remove LA and Grow LA (‘Swiss cheese’ procedure) 
vii. Remove MA and MS 
viii. Distri. MA and MS 
 
 
Figure 49.   The top view of Tablet F (flat-face) compressed at 7 kN created by PAC module 
of F-CAD with permission from CINCAP GmbH. 
Red: MA, Green: LA, Blue: MS, Yellow: HPC SL and Gray: Mg-St. 
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5.7.5.3 Dissolution Simulation (DS) operation 
DS module can compute the specific time elapsed until the water is detected at the 
geometric center of the virtual tablet in accordance to setting value of individual component 
regarding to the water-solubility, swellability and hydrophilicity of pores defined in Table 15 
as a surrogate as “Pore water solubility”. However, it is not currently possible to compute this 
specific time in case there is no API in the tablet created by PAC modules. From a principal 
point of view, it would be possible to calculate with F-CAD the dissolution profile of lactose 
(LA) as a hydrophilic and well soluble ingredient (filler) and to determine the specific time till 
the water molecules have reached the geometrical center of the tablet. However, in this PhD 
work the dissolution profile of lactose was not calculated. 
 
Table 15   Setting value of individual component 
Setting values Components 
(F-CAD classification) Water-solubility Swellability 
MA (API) 27,000 0 
LA (Non-swelling, soluble fillers)        65 0 
MS (Spherical disintegrant, swelling)      500 5 
HPC SL (Non-swelling, soluble binders)       690 5 
Mg-St (Hydrophobic ingredient) 65,000 0 
Porosity (Pore)          5 0 
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6 Results and Discussion 
6.1 Physical properties of starting materials 
MA, is a nonsteroidal anti-inflammatory agent classified as Class II on the basis of the 
biopharmaceutical classification system [25, 116] because of its poor solubility over the pH 
range 1.2 to 7.5 (Solubility: 0.2 g/mL (pH 1.2), 0.029 mg/mL (JP 2, pH 6.8), 0.12 mg/mL (pH 
7.5)) [117, 118] and high permeability in Caco-2 cell model (Permeability coefficient = 17.9 ± 
0.4 × 10-6 cm/sec) [118]. 
The mean diameter of MA, LA and MS was 6.57, 39.4, and 25.0 m, respectively. MA was 
agglomerated by fine powder. The shape of each component was almost spherical, not 
fibrous according to their SEM pictures. The true density of MA was determined to be 1.26 
g/cm3 which was much lower than that of LA and MS. Specific surface area (SSA) of MA was 
found to be 1.87 m2/g, which was much higher than that of LA and MS. 
6.2 Granules characterization 
6.2.1 Influence of loading volume of MA on granule characteristics 
The characteristics of granules with increasing loading volume of MA in exchange of 
lactose/maize starch (7/3) [42] as excipients from Granule A to H are given in Table 16a. 
During the granulation process it was important to adopt the relatively low fluidized air 
pressure in order to avoid adherence of starting materials to the upper part of the fluidized 
bed granulator. MA is well known to be difficult to handle in fluidized bed granulation and 
tableting processes due to the tendency to stick to surfaces [119]. Special attention was paid 
to keep the bed expansion constant during the whole granulation process. The apparent 
density of granules was decreasing with increasing loading volume of MA, although the 
mean diameter, bulk and tapped density was independent thereof. In terms of granules 
flowability, the flowability was no issue on the basis of Carr's index and Hausner ratio 
regardless of the loading volume of MA. 
The MA content of Granule B-C, D-E and F-H were determined to be 85-87%, 91-94% and 
97-98% in comparison with the theoretical content, respectively. The decrease of MA content 
determined to be 85-94% for the loading volume from 12.0-45.0% v/v can be explained by 
the attachment of MA particles to the inner surface of the fluidized bed granulator. This was 
attributed to the tendency of MA to stick to any type of surface. The decrease of MA content 
with the loading volume from 55.1-74.1% v/v can be explained that a small fraction, i.e. 2-3%, 
of MA powder can pass through the filter unit which has a pore size of 10 m. It should be 
kept in mind that MA due to electrostatic effects easily forms agglomerates with a diameter 
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larger than 10 m. The loading volume of MA has to be taken into account for the 
manufacturing process of fluidized bed granulation.  
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Table 16a   Characteristics of Granule A to H 
Granule (Loading volume of MA, % v/v) 
/ Particle Size distribution (%) 
A (0) B (12.0) C (23.5) D (34.5) E (45.0) F (55.1) G (64.8) H (74.1)
710 m on 0.6 0.04 0  0.04 0.04 0 0.2 0  
500 m on 0.2 0.5 0.4  0.2 0.5 0.04 0.3 0.2  
355 m on 4.8 10.7 5.9  4.3 6.4 2.0 12.0 5.0  
250 m on 27.0 45.5 42.1  31.2 40.7 25.7 39.9 34.7  
180 m on 40.8 29.4 31.6  39.0 30.2 39.0 22.3 29.4  
125 m on 15.5 9.0 13.1  15.9 14.8 20.2 14.8 16.7  
90 m on 6.1 2.4 5.5  5.8 4.4 8.5 5.9 8.0  
90 m pass 5.0 2.4 1.2  3.7 3.0 4.6 4.6 6.0  
Mean diameter (m) 223 267 250  230 247 212 253 228  
Powder moisture before granulation (%) 2.32 2.13 2.78  2.32 2.68 2.50 1.37 0.79  
Granules moisture after drying (%) 1.89 1.99 3.20  2.49 2.04 1.61 1.39 1.08  
Yield (%) 97.0 95.0 94.6 91.5 93.8 93.9 90.4 92.1 
Bulk density (g/cm3) 0.387 0.329 0.320  0.308 0.335 0.315 0.358 0.342  
Tapped density (g/cm3) 0.426 0.373 0.363  0.354 0.382 0.363 0.413 0.392  
Hausner ratio 1.1 1.1 1.1 1.1 1.1 1.2 1.2 1.2 
Carr Index (%) 9.1 11.8 11.8 12.9 12.1 13.2 13.2 12.6 
Yield (500-90 m, %) 91.4 92.2 93.0 87.9 90.5 89.6 85.7 86.4 
Apparent density (g/cm3) 1.558 1.534 1.502  1.475 1.446 1.419 1.389 1.365  
Assay (%) 0 84.6 86.9  91.2 93.7 97.8 97.0 97.9  
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Table 16b   Characteristics of Granule I to O 
Granule (Loading volume of MA, % v/v) 
/ Particle size distribution (%) 
I (0) J (34.5) K (74.1) L (0) M(74.0) N (0) O (34.5)
710 m on 0 0 0  0 0 0 0 
500 m on 0.5 0.2 0  0.4 0.1 0.8 0.2 
355 m on 9.8 3.2 0.6  10.2 0.6 13.2 3.8 
250 m on 44.8 32.0 20.9  43.9 14.5 48.4 32.3 
180 m on 28.2 36.8 41.4  30.0 36.0 27.8 38.0 
125 m on 9.4 13.6 21.0  10.7 27.3 7.7 17.3 
90 m on 3.3 8.2 7.2  3.0 13.4 1.8 5.4 
90 m pass 4.0 6.0 8.9  2.0 8.0 0.4 3.1 
Mean diameter (m) 261 223 199  263 184 281 230 
Powder moisture before granulation (%) 1.23 2.50 1.59  2.49 1.57 1.80 1.22 
Granules moisture after drying (%) 1.32 0.80 0.69  1.78 1.93 1.48 0.89 
Yield (%) 91.8 93.4 88.1 95.6 89.6 99.1 95.2
Bulk density (g/cm3) 0.381 0.317 0.314  0.312 0.327 0.329 0.314 
Tapped density (g/cm3) 0.436 0.365 0.365  0.361 0.385 0.377 0.370 
Hausner ratio 1.1 1.2 1.2 1.2 1.2 1.1 1.2
Carr Index (%) 12.6 13.2 14.0 13.6 15.1 12.7 15.1
Yield (500-90 m, %) 87.6 87.6 80.2 93.3 82.3 98.0 92.1
Apparent density (g/cm3) 1.571 1.468 1.355  1.556 1.349 1.561 1.472 
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6.2.2 SEM of granules with increasing loading volume of MA 
The SEM of MA granules A, D, F and H corresponding to 0%, 34.5%, 55.1% and 74.1% v/v 
of MA magnified x 100 and x 350 are given in Figure 50a, 50b, 50c and 50d respectively. 
The LA and MS particles were clearly observed in Granule A. MA particles were granulated 
with nuclei of LA and MS particles in Granule D, F and H. In Granule H, however, almost LA 
and MS particles were covered by MA particle. The dissolution rate of MA from granules 
covered by MA such as Granule H is assumed to be slow. 
 
 
Figure 50a.   Left: Granule A (x 100) composed of 0% v/v MA. Right: Granule A (x 350) 
composed of 0% v/v MA. 
 
 
Figure 50b.   Left: Granule D (x 100) composed of 34.5% v/v MA. Right: Granule D (x 350) 
composed of 34.5% v/v MA. 
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Figure 50c.   Left: Granule F (x 100) composed on 55.1% v/v MA. Right: Granule F (x 350) 
composed on 55.1% v/v MA. 
 
 
Figure 50d.   Left: Granule H (x 100) composed on 74.1% v/v MA. Right: Granule H (x 350) 
composed on 74.1% v/v MA. 
 
6.2.3 Intrusion volume of mercury into granules with increasing loading volume of 
MA 
Intrusion volume of mercury into the granules prepared with increasing loading volume of 
MA showed that the volume of intragranular pore which is assumed to be lower than 14 m 
in diameter [112] was increasing with increasing loading volume of MA. It is assumed that 
MA particles attached each other by only the effect of binder, which is HPC SL in this study, 
without dissolving each other in the granules. The relationship between intragranular pore 
volume and apparent density of granules are shown in Table 17 and Figure 51. With 
increasing loading volume of MA, intragranular pore volume was increasing and apparent 
density of granules was decreasing, although mean diameter, bulk and tapped density of 
granules was independent thereof (Table 16a). This was attributed to the true density of MA 
powder determined to be 1.26 g/cm3 (Table 11), which was much lower than that of LA and 
MS in the granules. 
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Table 17   Intrusion volume of mercury into granules with increasing loading volume of MA 
Granule Intrusion volume (mL/g) 
(Loading volume of MA, % v/v) 
Apparent density
(g/cm3) Total > 14 m < 14 m
A (0) 1.558 1.921 1.729 0.193 
B (12.0) 1.534 2.112 1.837 0.275 
C (23.5) 1.502 2.308 2.014 0.294 
D (34.5) 1.475 2.485 2.213 0.272 
E (45.0) 1.446 2.189 1.849 0.340 
F (55.1) 1.419 2.427 2.038 0.388 
G (64.8) 1.389 2.114 1.704 0.411 
H (74.1) 1.365 2.170 1.781 0.389 
 
Loading volume of MA (% v/v)
A
pp
ar
en
t d
en
sit
y,
 g
/c
m
3 
(▲
)
In
tra
gr
an
ul
ar
 p
or
e 
vo
lu
m
e,
 m
L/
g 
(●
)
1.35
1.4
1.45
1.5
1.55
1.6
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0 10 20 30 40 50 60 70 80
r2 = 0.8844
r2 = 0.9982
 
Figure 51.   Relationship between intragranular pore volume (●) and apparent density (▲) 
of granules. 
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6.3 Tablet characterization 
6.3.1 Influence of loading volume of MA on compression behaviour 
The characteristics of the tablets compressed at 7.0 kN from granules with increasing 
loading volume of MA in exchange of LA/MS (7/3) as excipients from Tablet A to H are given 
in Table 18a. The tensile force of Tablet A, B-E and F-H were 103, 128-134 and 142-143 
N/cm2 respectively (Figure 52). Tensile strength of MA tablet can be divided into two groups 
either Tablet B-E or F-H depending on the loading volume of MA. This was related to the 
following considerations; 
 Porosity of MA tablet gradually decreased (Table 18a). 
 MA particles in a tablet increased, which particle size was smaller than that of LA and 
MS (Table 11). 
 MA particles in a tablet increased due to the brittle behavior of MA during 
compression [119]. 
 Increasing intragranular porosity of granules was observed because the 
fragmentation of lactose granules with a high intragranular porosity before 
compaction was leading to smaller intergranular pores in the tablet [120, 121]. 
Linear increasing of thickness of tablets was also observed with increasing loading volume 
of MA (Figure 52). It was increasing with decreasing of apparent density of granules 
compressed into tablet as shown in Table 19 and Figure 53. It can be concluded that 
thickness of tablet is completely decided by the apparent density of granules used for 
compression. 
The ejection force of tablets which is the friction between the die wall and the tablet surface 
resulting from compression process increased with increasing loading volume of MA (Figure 
54). This was also attributed to the tendency of MA to stick to any type of surface [119]. The 
ejection force of tablet has to be taken into account for the manufacturing process of 
tableting although there was no capping of tablet tendency in this experiment due to the 
granules manufactured by fluidized bed granulator with spraying the HPC SL binder solution 
[43]. 
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Table 18a   Characteristics of Tablet A to H compressed at 7 kN 
Tablet 
(Loading volume of MA, % v/v) 
Weight 
(mg) 
Diameter 
(mm) 
Thickness 
(mm) 
Tensile strength 
(N/cm2) 
Cal. Porosity 
(%) 
Ejection force 
(N) 
A (0) 417.7 ± 0.82 
(n=6) 
10.0 ± 0.00 
(n=6) 
4.30 ± 0.01 
(n=6)  
103 ± 3.20
(n=6) 
20.6 ± 0.32 
(n=6) 
109 ± 11.4 
(n=26) 
B (12.0) 416.5 ± 1.10 
(n=6) 
10.0 ± 0.01 
(n=6) 
4.24 ± 0.01 
(n=6)  
128 ± 4.64
 (n=6) 
18.2 ± 0.21 
(n=6) 
231 ± 8.57 
(n=19) 
C (23.5) 415.6 ± 1.07 
(n=7) 
9.96 ± 0.01 
(n=7) 
4.28 ± 0.01 
(n=7)  
133 ± 3.60 
(n=7) 
17.0 ± 0.28 
(n=7) 
357 ± 18.1 
(n=20) 
D (34.5) 417.5 ± 1.32 
(n=7) 
9.96 ± 0.01 
(n=7) 
4.35 ± 0.01 
(n=7)  
132 ± 3.89 
(n=7) 
16.6 ± 0.28 
(n=7) 
505 ± 18.6 
(n=19) 
E (45.0) 416.5 ± 0.73 
(n=6) 
9.97 ± 0.01 
(n=6) 
4.41 ± 0.01 
(n=6)  
134 ± 3.35 
(n=6) 
16.2 ± 0.20 
(n=6) 
593 ± 12.2 
(n=18) 
F (55.1) 416.7 ± 1.40 
(n=6) 
9.97 ± 0.01 
(n=6) 
4.47 ± 0.01 
(n=6)  
143 ± 7.14
 (n=6) 
15.8 ± 0.24 
(n=6) 
703 ± 22.5 
(n=18) 
G (64.8) 417.7 ± 0.55 
(n=6) 
9.97 ± 0.00 
(n=6) 
4.56 ± 0.00 
(n=6)  
142 ± 4.76
 (n=6) 
15.5 ± 0.14 
(n=6) 
697 ± 27.9 
(n=18) 
H (74.1) 416.9 ± 1.72 
(n=6) 
10.0 ± 0.01 
(n=6) 
4.65 ± 0.01 
(n=6)  
143 ± 3.52 
(n=6) 
16.4 ± 0.37 
(n=6) 
802 ± 19.6 
(n=18) 
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Table 18b   Characteristics of Tablet I to O compressed at 7 kN 
Tablet 
(Loading volume of MA, % v/v) 
Weight 
(mg) 
Diameter 
(mm) 
Thickness 
(mm) 
Tensile strength 
(N/cm2) 
Cal. Porosity 
(%) 
Ejection force 
(N) 
I (0) 416.6 ± 0.43 
(n=6) 
10.0 ± 0.00 
(n=6) 
4.26 ± 0.01 
(n=6)  
97.6 ± 2.71
(n=6) 
20.6 ± 0.16 
(n=6) 
209 ± 11.0 
(n=24) 
J (34.5) 415.0 ± 0.62 
(n=6) 
10.0 ± 0.00 
(n=6) 
4.34 ± 0.02 
(n=6)  
135 ± 2.10
 (n=6) 
17.0 ± 0.26 
(n=6) 
583 ± 12.9 
(n=24) 
K (74.1) 414.6 ± 1.02 
(n=6) 
10.0 ± 0.00 
(n=6) 
4.66 ± 0.02 
(n=6)  
129 ± 1.95 
(n=6) 
16.3 ± 0.32 
(n=6) 
989 ± 18.9 
(n=25) 
L (0) 417.5 ± 0.31 
(n=6) 
9.99 ± 0.01 
(n=6) 
4.27 ± 0.01 
(n=6)  
118 ± 1.96 
(n=6) 
19.7 ± 0.15 
(n=6) 
188 ± 18.6 
(n=14) 
M (74.0) 416.6 ± 0.75 
(n=6) 
9.99 ± 0.00 
(n=6) 
4.70 ± 0.01 
(n=6)  
131 ± 2.17 
(n=6) 
16.2 ± 0.11 
(n=6) 
1094 ± 38.4 
(n=17) 
N (0) 417.2 ± 0.48 
(n=6) 
9.99 ± 0.00 
(n=6) 
4.28 ± 0.02 
(n=6)  
125 ± 4.07
 (n=6) 
20.4 ± 0.47 
(n=6) 
323 ± 8.59 
(n=16) 
O (34.5) 417.2 ± 0.62 
(n=6) 
10.0 ± 0.01 
(n=6) 
4.38 ± 0.01 
(n=6)  
133 ± 4.58 
(n=6) 
17.4 ± 0.29 
(n=6) 
729 ± 17.8 
(n=22) 
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Table 18c   Characteristics of Tablet A to H compressed at 5 kN 
Tablet 
(Loading volume of MA, % v/v) 
Weight 
(mg) 
Diameter 
(mm) 
Thickness 
(mm) 
Tensile strength 
(N/cm2) 
Cal. Porosity 
(%) 
Ejection force 
(N) 
A (0) 416.1 ± 0.31 
(n=3) 
9.94 ± 0.01 
(n=3) 
4.62 ± 0.01 
(n=3)  
58.3 ± 0.16
(n=3) 
25.4 ± 0.22 
(n=3) 
183 ± 6.46 
(n=18) 
B (12.0) 415.6 ± 0.95 
(n=3) 
9.93 ± 0.01 
(n=3) 
4.62 ± 0.01 
(n=3)  
67.5 ± 2.14
 (n=3) 
24.3 ± 0.28 
(n=3) 
265 ± 8.24 
(n=18) 
C (23.5) 415.4 ± 0.75 
(n=3) 
9.93 ± 0.01 
(n=3) 
4.64 ± 0.01 
(n=3)  
70.1 ± 2.12 
(n=3) 
23.0 ± 0.14 
(n=3) 
342 ± 7.21 
(n=18) 
D (34.5) 416.4 ± 0.06 
(n=3) 
9.92 ± 0.01 
(n=3) 
4.66 ± 0.02 
(n=3)  
80.4 ± 1.77 
(n=3) 
21.6 ± 0.16 
(n=3) 
423 ± 7.14 
(n=18) 
E (45.0) 415.1 ± 0.83 
(n=3) 
9.93 ± 0.00 
(n=3) 
4.71 ± 0.01 
(n=3)  
79.0 ± 1.28 
(n=3) 
21.2 ± 0.07 
(n=3) 
495 ± 9.85 
(n=18) 
F (55.1) 416.1 ± 0.60 
(n=3) 
9.93 ± 0.01 
(n=3) 
4.77 ± 0.01 
(n=3)  
88.4 ± 0.86
 (n=3) 
20.5 ± 0.20 
(n=3) 
633 ± 16.5 
(n=18) 
G (64.8) 416.4 ± 0.12 
(n=3) 
9.94 ± 0.01 
(n=3) 
4.86 ± 0.01 
(n=3)  
84.8 ± 1.36
 (n=3) 
20.5 ± 0.22 
(n=3) 
701 ± 13.8 
(n=18) 
H (74.1) 417.2 ± 0.76 
(n=3) 
9.93 ± 0.00 
(n=3) 
4.95 ± 0.01 
(n=3)  
92.5 ± 0.53 
(n=3) 
20.2 ± 0.05 
(n=3) 
865 ± 13.3 
(n=18) 
 
80 
 
Table 18d   Characteristics of Tablet I to O compressed at 5 kN 
Tablet 
(Loading volume of MA, % v/v) 
Weight 
(mg) 
Diameter 
(mm) 
Thickness 
(mm) 
Tensile strength 
(N/cm2) 
Cal. Porosity 
(%) 
Ejection force 
(N) 
I (0) 416.5 ± 0.64 
(n=3) 
9.99 ± 0.00 
(n=3) 
4.48 ± 0.02 
(n=3)  
70.2 ± 1.87
(n=3) 
24.5 ± 0.36 
(n=3) 
190 ± 12.1 
(n=20) 
J (34.5) 416.0 ± 0.76 
(n=3) 
9.99 ± 0.01 
(n=3) 
4.60 ± 0.00 
(n=3)  
91.5 ± 1.34
 (n=3) 
21.3 ± 0.10 
(n=3) 
495 ± 13.6 
(n=19) 
K (74.1) 415.3 ± 0.78 
(n=3) 
9.99 ± 0.01 
(n=3) 
4.96 ± 0.01 
(n=3)  
83.5 ± 2.70 
(n=3) 
21.2 ± 0.28 
(n=3) 
816 ± 22.8 
(n=18) 
L (0) 413.7 ± 0.61 
(n=3) 
9.99 ± 0.00 
(n=3) 
4.53 ± 0.01 
(n=3)  
69.9 ± 1.76 
(n=3) 
25.1 ± 0.10 
(n=3) 
190 ± 5.06 
(n=18) 
M (74.0) 414.2 ± 0.06 
(n=3) 
10.0 ± 0.00 
(n=3) 
4.94 ± 0.01 
(n=3)  
87.2 ± 0.70 
(n=3) 
20.9 ± 0.09 
(n=3) 
807 ± 21.8 
(n=19) 
N (0) 416.3 ± 0.62 
(n=3) 
9.98 ± 0.01 
(n=3) 
4.46 ± 0.02 
(n=3)  
87.4 ± 1.83
 (n=3) 
23.4 ± 0.48 
(n=3) 
221 ± 9.04 
(n=19) 
O (34.5) 415.6 ± 0.95 
(n=3) 
9.99 ± 0.00 
(n=3) 
4.58 ± 0.02 
(n=3)  
90.4 ± 1.33 
(n=3) 
21.4 ± 0.09 
(n=3) 
482 ± 18.5 
(n=18) 
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Table 18e   Characteristics of Tablet A to H compressed at 3 kN 
Tablet 
(Loading volume of MA, % v/v) 
Weight 
(mg) 
Diameter 
(mm) 
Thickness 
(mm) 
Tensile strength 
(N/cm2) 
Cal. Porosity 
(%) 
Ejection force 
(N) 
A (0) 416.2 ± 0.57 
(n=3) 
9.94 ± 0.01 
(n=3) 
5.03 ± 0.00 
(n=3)  
28.0 ± 0.02
(n=3) 
31.6 ± 0.03 
(n=3) 
119 ± 4.54 
(n=18) 
B (12.0) 416.3 ± 0.55 
(n=3) 
9.93 ± 0.00 
(n=3) 
5.01 ± 0.01 
(n=3)  
36.3 ± 0.68
 (n=3) 
30.0 ± 0.08 
(n=3) 
170 ± 3.89 
(n=18) 
C (23.5) 415.8 ± 1.18 
(n=3) 
9.93 ± 0.01 
(n=3) 
5.00 ± 0.01 
(n=3)  
38.5 ± 0.06 
(n=3) 
28.5 ± 0.28 
(n=3) 
238 ± 7.33 
(n=18) 
D (34.5) 416.2 ± 0.62 
(n=3) 
9.93 ± 0.01 
(n=3) 
5.02 ± 0.01 
(n=3)  
43.5 ± 1.26 
(n=3) 
27.4 ± 0.11 
(n=3) 
292 ± 5.82 
(n=18) 
E (45.0) 416.8 ± 0.64 
(n=3) 
9.93 ± 0.00 
(n=3) 
5.03 ± 0.01 
(n=3)  
48.4 ± 1.28 
(n=3) 
26.0 ± 0.12 
(n=3) 
342 ± 17.6 
(n=18) 
F (55.1) 415.0 ± 0.56 
(n=3) 
9.92 ± 0.01 
(n=3) 
5.09 ± 0.02 
(n=3)  
52.6 ± 2.12
 (n=3) 
25.6 ± 0.28 
(n=3) 
432 ± 11.9 
(n=18) 
G (64.8) 416.8 ± 0.55 
(n=3) 
9.92 ± 0.01 
(n=3) 
5.21 ± 0.01 
(n=3)  
52.2 ± 0.83
 (n=3) 
25.5 ± 0.34 
(n=3) 
457 ± 8.79 
(n=18) 
H (74.1) 416.6 ± 0.61 
(n=3) 
9.93 ± 0.01 
(n=3) 
5.28 ± 0.01 
(n=3)  
56.9 ± 0.82 
(n=3) 
25.2 ± 0.11 
(n=3) 
580 ± 12.4 
(n=18) 
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Table 18f   Characteristics of Tablet I to O compressed at 3 kN 
Tablet 
(Loading volume of MA, % v/v) 
Weight 
(mg) 
Diameter 
(mm) 
Thickness 
(mm) 
Tensile strength 
(N/cm2) 
Cal. Porosity 
(%) 
Ejection force 
(N) 
I (0) 416.1 ± 0.38 
(n=3) 
9.99 ± 0.00 
(n=3) 
4.87 ± 0.01 
(n=3)  
34.9 ± 0.78
(n=3) 
30.5 ± 0.08 
(n=3) 
118 ± 7.43 
(n=18) 
J (34.5) 416.4 ± 0.55 
(n=3) 
9.99 ± 0.01 
(n=3) 
4.99 ± 0.01 
(n=3)  
47.7 ± 0.85
 (n=3) 
27.4 ± 0.29 
(n=3) 
347 ± 15.0 
(n=19) 
K (74.1) 415.7 ± 0.36 
(n=3) 
10.0 ± 0.00 
(n=3) 
5.38 ± 0.01 
(n=3)  
46.2 ± 2.01 
(n=3) 
27.3 ± 0.10 
(n=3) 
540 ± 16.1 
(n=18) 
L (0) 415.5 ± 1.00 
(n=3) 
9.99 ± 0.00 
(n=3) 
4.93 ± 0.02 
(n=3)  
34.9 ± 1.30 
(n=3) 
30.9 ± 0.09 
(n=3) 
141 ± 8.26 
(n=18) 
M (74.0) 415.9 ± 0.71 
(n=3) 
10.0 ± 0.00 
(n=3) 
5.39 ± 0.01 
(n=3)  
43.3 ± 1.88 
(n=3) 
27.2 ± 0.26 
(n=3) 
551 ± 11.7 
(n=19) 
N (0) 417.0 ± 0.38 
(n=3) 
9.98 ± 0.00 
(n=3) 
4.88 ± 0.01 
(n=3)  
41.9 ± 0.09
 (n=3) 
30.0 ± 0.20 
(n=3) 
169 ± 7.62 
(n=19) 
O (34.5) 417.1 ± 0.40 
(n=3) 
9.99 ± 0.00 
(n=3) 
4.98 ± 0.02 
(n=3)  
50.4 ± 0.84 
(n=3) 
27.3 ± 0.25 
(n=3) 
300 ± 13.5 
(n=18) 
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Figure 52.   Thickness and tensile strength of tablets compressed at 7.0 kN from granules 
with increasing loading volume of MA. 
 
Table 19   Relationship between apparent density of granules and tablet thickness 
compressed at 7.0 kN 
Granule Thickness (mm) 
(Loading volume of MA, % v/v) 
Apparent density
(g/cm3) Average S.D. 
A (0) 1.558 4.30 0.01 
B (12.0) 1.534 4.24 0.01 
C (23.5) 1.502 4.28 0.01 
D (34.5) 1.475 4.35 0.01 
E (45.0) 1.446 4.41 0.01 
F (55.1) 1.419 4.47 0.01 
G (64.8) 1.389 4.56 0.004 
H (74.1) 1.365 4.65 0.01 
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Figure 53.   Relationship between apparent density of granules and tablet thickness 
compressed at 7.0 kN. 
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Figure 54.   Relationship between loading volume of MA and ejection force of tablets 
compressed at 7.0 kN. 
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6.3.2 Visual inspection on tablet characteristics using NIR imaging 
In order to get the more scientific understanding of the tablet characteristics, especially for 
tensile strength of tablet, near infrared (NIR) imaging technology has been applied to 
visualize their component distribution on the tablet surface compressed at 7.0 kN according 
to the loading volume of MA. Figure 55 shows the distribution of the predicted concentration 
for MA, LA, MS by partial least square regression (PLSR) technique on one surface of each 
tablet from A to H. The intensity spectral from a second derivative calculation was illustrated 
as a color. MA, LA and MS were showed by Red, Green and Blue respectively and overlaid 
as a Red-Green-Blue (RGB) imaging [55]. 
MA has been well distributed homogenously with increasing the loading volume of MA from 
RGB imaging visually. In Tablet H, LA and MS particles are located on the surface of tablet 
although LA and MS particles are covered by MA particles in the Granules H. LA and MS 
particles should be located in order to induce the water into tablet for the disintegration. 
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Figure 55a.   RGB imaging of Tablet A (MA: 0% w/w). 
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Figure 55b.   RGB imaging of Tablet B (MA: 10% w/w, 12.0% v/v). 
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Figure 55c.   RGB imaging of Tablet C (MA: 20% w/w, 23.5% v/v). 
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Figure 55d.   RGB imaging of Tablet D (MA: 30% w/w, 34.5% v/v). 
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Figure 55e.   RGB imaging of Tablet E (MA: 40% w/w, 45.0% v/v). 
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Figure 55f.   RGB imaging of Tablet F (MA: 50% w/w, 55.1% v/v). 
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Figure 55g.   RGB imaging of Tablet G (MA: 60% w/w, 64.8% v/v). 
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Figure 55h.   RGB imaging of Tablet H (MA: 70% w/w, 74.1% v/v). 
 
6.3.3 MA domain size with increasing loading volume of MA in tablet 
Mean domain size of each component on the surface of tablets compressed at 7.0 kN was 
determined by the pixel size of NIR imaging as shown in Table 20 and Figure 56. The 
domain size of MA was increasing up to the 45.0% v/v (Tablet E) loading volume of MA. 
Then its domain size was decreasing with increasing the loading volume of MA up to the 
74.1% v/v (Tablet H) although the domain size of LA and MS was kept constant. This 
revealed that the decreasing the domain size of MA also resulted in increasing the tensile 
strength of tablet due to increase the number of MA particle in tablet because the tensile 
strength of tablet has jumped from Tablet E to F corresponding to 45.0% v/v to 55.1% v/v of 
MA in Figure 52. It is concluded MA is key attribute on the tablet characteristics in terms of 
thickness and tensile strength as compared with LA and MS. 
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Table 20   Mean domain size of MA, LA and MS on the tablet surface 
Tablet Mean domain size (m) 
(Loading volume of MA, % v/v) MA LA MS 
A (0) ― 104 94.3
B (12.0) 171 95.2 83.4
C (23.5) 193 97.1 74.0
D (34.5) 211 104 83.0
E (45.0) 211 111 85.3
F (55.1) 177 123 81.4
G (64.8) 137 138 74.8
H (74.1) 83.2 118 82.9
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Figure 56.   Mean domain size of MA (●), LA (▲) and MS (■) on the tablet surface with 
increasing loading volume of MA. 
 
6.3.4 Tablet disintegration time 
The disintegration process is an important factor for drug dissolution, especially for drugs 
with low solubility in water or in gastrointestinal fluids. The disintegration time of tablets 
compressed at 7.0 kN was roughly constant up to 34.5% v/v (Tablet D) loading volume of MA, 
and then decreased to a minimum with 55.1% v/v (Tablet F) loading volume of MA and finally 
increased again with increasing the loading volume of MA up to 74.1% v/v (Tablet H) as 
shown in Table 21 and Figure 57. The decreasing volume of MS in the tablet as a 
disintegrant from 30.3% v/v to 13.6% v/v corresponding to the increasing loading volume of 
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MA from 0% v/v to 55.1% v/v is suggested to have a positive influence on the disintegration 
process [122]. 
Leuenberger et al. found the amount (% v/v) of StaRX1500® corresponded to the critical 
concentration, i.e. to the percolation threshold in terms of percolation theory, of StaRX1500® 
for binary mixture: caffeine or paracetamol - StaRX1500® [9-12]. It is important to mention 
here that percolation threshold of disintegrant is also found for an immediate release of a 
realistic pharmaceutical tablet formulation in this study. 
 
Table 21   Disintegration time of tablets compressed at 7.0 kN 
Tablet 
(Loading volume of MA, % v/v) 
Disintegration time (sec.) 
(n=3) 
A (0) 550 ± 23 
B (12.0) 596 ±   8 
C (23.5) 616 ±   6 
D (34.5) 604 ± 21 
E (45.0) 428 ± 16 
F (55.1) 266 ±   8 
G (64.8) 453 ± 24 
H (74.1) 758 ± 15 
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Figure 57.   Disintegration time of tablets compressed at 7.0 kN with increasing loading 
volume of MA. The volume (% v/v) of MS in tablet is represented in brackets.
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6.3.5 Pore size distribution, Median pore diameter and porosity 
In order to consider the other factors related to the minimum disintegration time of tablet 
compressed at 7.0 kN, which was found with 55.1% v/v (Tablet F) loading volume of MA 
[122], the pore size distribution, median pore diameter by volume and porosity of tablet were 
investigated. The pore diameter of tablets compressed from granules prepared at different 
loading volumes of MA corresponding to the intrusion volume of mercury was plotted to show 
the pore size distribution of tablet (Figure 58). With increasing loading volume of MA, the 
volume of large pore of tablet was decreasing and the peak of pore size distribution was 
shifting towards the smaller pore diameter. The median pore diameter and porosity are 
shown in Table 22. The median pore diameter and porosity of tablets was gradually 
decreasing with increasing loading volume of MA which was same results with when porosity 
was calculated by Equation 25. It is suggested that the calculated porosity is enough to 
evaluate the tablet properties in this study. This linear trend was not observed with the 
results obtained by measuring the disintegration time of the tablets. It can be concluded that 
the pore diameter and porosity of tablet was not a significant parameter in this study to 
explain the minimum disintegration time which was found with 55.1% v/v (Tablet F) loading 
volume of MA. Further, it can be concluded that the dominant factor on disintegration for MA 
tablets was the swelling property of MS in the tablet. The critical concentration of disintegrant 
(% v/v) can exert the swelling property on the surrounding particles and induce water for 
more effective disintegration of the tablet. 
Below and above the critical concentration of disintegrant, the disintegration time was 
increasing, giving a typical V-shape curve. The increase of disintegration time above the 
critical concentration of disintegrant was assumed so far as followings; 
 There is not enough space for disintegrant particles to expand in the tablet. The 
excess of disintegrant particles might start retarding the swelling properties of MS 
each other [122]. 
 The continuous cluster of disintegrant particles or pores conducting water might starts 
to extend by forming dead-end arms from the backbone (excess of disintegrant). The 
increased complexity of the network retards the penetration of water within the tablet 
as compared with the continuous cluster at the percolation threshold [12]. 
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Figure 58.   Pore size distribution of tablets compressed at 7.0 kN with increasing loading 
volume of MA. 
 
Table 22   Median pore diameter, Porosity of tablets compressed at 7.0 kN 
 Median pore diameter (m) 
(n=1) 
Porosity (%)
(n=1) 
Cal. Porosity (% v/v) 
(n=6-7) 
∆ % 
A 1.365 22.3 20.6 ± 0.32 1.7 
B 0.893 20.4 18.2 ± 0.21 2.2 
C 0.620 19.6 17.0 ± 0.28 2.6 
D 0.483 19.4 16.6 ± 0.28 2.8 
E 0.341 18.6 16.2 ± 0.20 2.4 
F 0.307 18.5 15.8 ± 0.24 2.7 
G 0.255 18.1 15.5 ± 0.14 2.6 
H 0.232 17.9 16.4 ± 0.37 1.5 
 
6.4 Focus on searching the critical concentration of MS 
The minimum disintegration time (266 ± 8 sec.) of tablet compressed at 7.0 kN for MA 
tablet has been determined for a ternary composition of 55.1% v/v (50% w/w) MA, 31.3% v/v 
(35% w/w) LA and 13.6% v/v (15% w/w) MS [122]. However, it has to be kept in mind that it 
was not a truly ternary components system as the ratio of LA/MS (7/3) was kept constant 
[122]. In the following section, the ratio of LA to MS has been extended to correspond to a 
truly ternary components tablet formulation [123]. It also has to be kept in mind again that up 
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to now there is no universal science-based formulation technique for low water soluble drugs. 
Therefore several research groups reported about the critical concentration of disintegrant 
that is required to achieve the minimum disintegration time [2-6]. Determination of the critical 
concentration of disintegrant is an important parameter for design of a tablet formulation, 
especially for low water soluble drugs as mentioned above, to increase the specific surface 
area by an optimal and fast disintegration. 
Ringard and Guyot-Hermann [7] have introduced the following equation for the calculation 
of the most effective disintegrant concentration by taking into account the geometrical 
description of the involved particles (drug or filler, disintegrant) and the change of the particle 
size of the disintegrant due to swelling (Equation 29). 
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                                                                     Equation (29) 
where Ms is an optimal amount of disintegrant (w/w), ρ1, ρ2 (g/cm3) are true densities of 
disintegrant and active substance respectively; D1, D2 are average diameters (Ferret’s 
diameters) of dry disintegrant particles and active substance, respectively; D1s is an 
average diameter of the swollen disintegrant particle. 
 
This equation was described by assuming that the fine particles of the disintegrant form an 
“infinite” network and cover totally the surface of the coarser drug particles. 
Krausbauer, Puchkov and Leuenberger [11, 12] have finally proposed the caging and non-
caging concept (Equation 14) in order to calculate the critical concentration of non-fibrous 
disintegrant in a binary tablets composed of caffeine or paracetamol and partially 
pregelatinized maize starch, StaRX1500®. 
However the further investigation is needed to determine the critical concentration of non-
fibrous disintegrant not only for binary tablets but also for ternary pharmaceutical tablets. No 
one, however, has reported experimentally the location of critical concentration of 
disintegrant for a ternary immediate release pharmaceutical tablet formulation. 
The holistic description is an important issue as formulations are complex systems such as 
pharmaceutical tablet formulation and its quality of the product depends on the variability of 
the manufacturing processes involved and on the variability of the physical and chemical 
quality of the components in the tablet. The number of compositions has increased and each 
composition of granules was compressed at not only 7 kN but also 5 kN and 3 kN. Thus the 
results of the tensile strength, porosity and disintegration time are listed in Table 23 as a 
physical description and documentation of the tablet quality. 
Figure 59 shows the response surfaces of disintegration MA tablets compressed at 7 kN, 5 
kN and 3 kN as a function of MA (% v/v) and MS (% v/v). Minimum disintegration time of 
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tablets compressed at 7 kN and 5 kN was found for the Tablet O, F and M corresponding to 
34.5% v/v, 55.1% v/v and 74.0% v/v of MA respectively. The minimum disintegration time of 
MA tablets was surprisingly observed at a ratio of MS/MA = 0.25. However, a catastrophic 
change reading to disintegration time of MA tablets compressed at 3 kN was not strongly 
observed. The dominant network that the water can diffuse for the disintegration of MA tablet 
is considered through the disintegrant network, not through the porous network. On the other 
hand, the disintegration time of Tablet A, I, L and N corresponding to 0% v/v of MA was 
almost constant regardless of the porosity of tablet. 
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Figure 59a.   Response surfaces of disintegration MA tablets compressed at 7 kN as a 
function of MA (% v/v) and MS (% v/v). 
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Figure 59b.   Response surfaces of disintegration MA tablets compressed at 5 kN as a 
function of MA (% v/v) and MS (% v/v). 
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Figure 59c.   Response surfaces of disintegration MA tablets compressed at 3 kN as a 
function of MA (% v/v) and MS (% v/v). 
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Table 23   Holistic investigation of characteristics of MA tablets 
 7 kN 5 kN 3 kN 
 
MS/MA 
Porosity TS TDis Porosity TS TDis Porosity TS TDis 
 
Composition (% v/v) 
 (% v/v) (N/cm2) (sec.) (% v/v) (N/cm2) (sec.) (% v/v) (N/cm2) (sec.) 
 MA LA MS  (n=6-7) (n=6-7) (n=3) (n=3) (n=3) (n=3) (n=3) (n=3) (n=3) 
A  0 69.7 30.3 - 20.6 ± 0.32 103 ± 3.20 550 ± 23 25.4 ± 0.22 58.3 ± 0.16 517 ± 22 31.6 ± 0.03 28.0 ± 0.02 554 ± 28 
B 12 61.4 26.6 2.217 18.2 ± 0.21 128 ± 4.64 596 ±   8 24.3 ± 0.28 67.5 ± 2.14 573 ± 23 30.0 ± 0.08 36.3 ± 0.68 593 ± 21 
C 23.5 53.4 23.1 0.983 17.0 ± 0.28 133 ± 3.60 616 ±   6 23.0 ± 0.14 70.1 ± 2.12 644 ± 14 28.5 ± 0.28 38.5 ± 0.06 715 ± 71 
D 34.5 45.7 19.8 0.574 16.6 ± 0.28 132 ± 3.89 604 ± 21 21.6 ± 0.16 80.4 ± 1.77 627 ±   8 27.4 ± 0.11 43.5 ± 1.26 734 ± 19 
E 45.0 38.4 16.6 0.369 16.2 ± 0.20 134 ± 3.35 428 ± 16 21.2 ± 0.07 79.0 ± 1.28 589 ± 25 26.0 ± 0.12 48.4 ± 1.28 728 ± 31 
F 55.1 31.3 13.6 0.247 15.8 ± 0.24 143 ± 7.14 266 ±   8 20.5 ± 0.20 88.4 ± 0.86 418 ± 11 25.6 ± 0.28 52.6 ± 2.12 619 ± 21 
G 64.8 24.6 10.6 0.164 15.5 ± 0.14 142 ± 4.76 453 ± 24 20.5 ± 0.22 84.8 ± 1.36 403 ± 11 25.5 ± 0.34 52.2± 0.83 658 ± 25 
H 74.1 18.1  7.8 0.105 16.4 ± 0.37 143 ± 3.52 758 ± 15 20.2 ± 0.05 92.5 ± 0.53 461 ± 15 25.2 ± 0.11 56.9 ± 0.82 518 ± 15 
I 0 84.8 15.2 - 20.6 ± 0.16 97.6 ± 2.71 379 ±   7 24.5 ± 0.36 70.2 ± 1.87 312 ±   7 30.5 ± 0.08 34.9 ± 0.78 281 ± 14 
J 34.5 51.3 14.2 0.412 17.0 ± 0.26 135 ± 2.10 535 ± 12 21.3 ± 0.10 91.5 ± 1.34 633 ± 23 27.4 ± 0.29 47.7 ± 0.85 737 ± 24 
K 74.1 12.9 13.0 0.175 16.3 ± 0.32 129 ± 1.95 413 ±   8 21.2 ± 0.28 83.5 ± 2.70 392 ± 25 27.3 ± 0.10 46.2 ± 2.01 783 ± 15 
L  0 78.8 21.2 - 19.7 ± 0.15 118 ± 1.96 373 ± 36 25.1 ± 0.10 69.9 ± 1.76 339 ± 11 30.9 ± 0.09 34.9 ± 1.30 339 ± 54 
M 74.0  7.7 18.3 0.247 16.2 ± 0.11 131 ± 2.17 290 ±   2 20.9 ± 0.08 87.2 ± 0.70 373 ± 17 27.2 ± 0.26 43.3 ± 1.88 713 ± 25 
N  0 90.9  9.1 - 20.4 ± 0.47 125 ± 4.07 232 ± 20 23.4 ± 0.48 87.4 ± 1.83 276 ± 25 30.0 ± 0.20 41.9 ± 0.09 256 ± 37 
O 34.5 57.0  8.5 0.246 17.4 ± 0.29 133 ± 4.58 420 ±   9 21.4 ± 0.09 90.4 ± 1.33 561 ± 17 27.4 ± 0.25 50.4 ± 0.84 589 ± 10 
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6.5 Renormalization technique considerations 
The current study is focused on ternary formulation: MA, LA, MS. In order to establish the 
connectivity to the binary systems, the renormalization leading to a dimension reduction was 
applied. The renormalization is mainly a technique to map three dimensional data down to 
two dimensions (Figure 60). Each volumetric percentage of MA and MS were expressed by 
MS/(MS+MA) as X axis. It is called as renormalized MS concentration. 
Figure 61 shows a plot of disintegration time of MA formulations compressed at 7 kN, 5 kN, 
and 3 kN with respect to renormalized MS concentration. This dimension reduction is only 
possible and allowed due to the dominating effect of MA in the formulation for concentrations 
of MA >> 23.5% (v/v), i.e. for concentrations (see Figure 60), that exceed the percolation 
threshold of MA (pcMA). Thus, in practice it is important and prerequisite to look only at 
formulations with a high dose of MA, i.e. with an MA load larger than 20% (w/w). It has to be 
noted that proposed renormalization is independent on the nature of a third component in the 
mixture. However, it should be applied with limitations. Reducing of third component is 
possible if the amount of third component’s particles is significantly less than of the particles 
of other components in the mixture. In the present case this is guaranteed by high load of MA. 
Another limitation is that third component should not have fibrous structure. 
It also has to be kept in mind that the evaluation of the Equation 15 according to the 
percolation theory is only allowed in the vicinity of the percolation threshold [74]. The regions 
of an initial steep fall and a following sharp rise of a tablet disintegration time are 
corresponding to the interval of the MS/(MS+MA) ratio from around 0.1 till 0.3 as shown in 
Figure 61. This region is followed by the leveling off the disintegration time at a constant 
value which is not shown in following section of this PhD work [cut off at 0.3]. 
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Figure 60.   Mapping from three dimensional data down to two dimensions when MA concentrations >> 23.5 % (v/v) regarding to the 
disintegration time of MA tablets compressed at 7 kN. 
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Figure 61.   Plot of disintegration time of MA formulations compressed at 7, 5, and 3 kN with 
respect to renormalized MS concentration. 
 
6.6 Critical concentration of MS for MA tablets 
The minimum disintegration time of tablets compressed at 7 kN and 5 kN was found for the 
Tablet O, F and M corresponding respectively to 34.5% v/v, 55.1% v/v and 74.0% v/v of MA 
was expressed at a renormalized MS concentration; MS/(MS+MA) = 0.198 using only the 
experimental values (Table 24). In fact, the renormalized MS concentration; MS/(MS+MA) = 
0.198 for high dose, i.e. > 20% (w/w) MA tablets corresponds to the critical concentration of 
MS and represents the percolation threshold of MS. Below and above this percolation 
threshold of the disintegration time was increasing. The absolute minimum of the 
disintegration time (266 ± 8 sec.) was found for MA tablet compressed with the force of 7 kN. 
This data set exhibits the most distinct percolation event with the sharper minimum of the 
disintegration time. For this reason this dataset was used for the evaluation of Equation 15. 
In Figure 62, the critical concentration of MS was calculated using the spline function with 
the dataNESIA software. It was leading to a slightly different minimum at 0.206, which was 
very close to 0.198. 
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Table 24   Holistic investigation of characteristics of MA tablets for renormalized MS concentrations 
 7 kN 5 kN 
 
MS/ 
(MS+MA) Porosity TS TDis Porosity TS TDis 
 
Composition (% v/v) 
 (% v/v) (N/cm2) (sec.) (% v/v) (N/cm2) (sec.) 
 MA LA MS  (n=6-7) (n=6-7) (n=3) (n=3) (n=3) (n=3) 
A  0 69.7 30.3 1 20.6 ± 0.32 103 ± 3.20 550 ± 23 25.4 ± 0.22 58.3 ± 0.16 517 ± 22
B 12 61.4 26.6 0.689 18.2 ± 0.21 128 ± 4.64 596 ±   8 24.3 ± 0.28 67.5 ± 2.14 573 ± 23
C 23.5 53.4 23.1 0.497 17.0 ± 0.28 133 ± 3.60 616 ±   6 23.0 ± 0.14 70.1 ± 2.12 644 ± 14
D 34.5 45.7 19.8 0.365 16.6 ± 0.28 132 ± 3.89 604 ± 21 21.6 ± 0.16 80.4 ± 1.77 627 ±   8
E 45.0 38.4 16.6 0.27 16.2 ± 0.20 134 ± 3.35 428 ± 16 21.2 ± 0.07 79.0 ± 1.28 589 ± 25
F 55.1 31.3 13.6 0.198 15.8 ± 0.24 143 ± 7.14 266 ±   8 20.5 ± 0.20 88.4 ± 0.86 418 ± 11
G 64.8 24.6 10.6 0.141 15.5 ± 0.14 142 ± 4.76 453 ± 24 20.5 ± 0.22 84.8 ± 1.36 403 ± 11
H 74.1 18.1  7.8 0.096 16.4 ± 0.37 143 ± 3.52 758 ± 15 20.2 ± 0.05 92.5 ± 0.53 461 ± 15
I 0 84.8 15.2 1 20.6 ± 0.16 97.6 ± 2.71 379 ±   7 24.5 ± 0.36 70.2 ± 1.87 312 ±   7
J 34.5 51.3 14.2 0.292 17.0 ± 0.26 135 ± 2.10 535 ± 12 21.3 ± 0.10 91.5 ± 1.34 633 ± 23
K 74.1 12.9 13.0 0.15 16.3 ± 0.32 129 ± 1.95 413 ±   8 21.2 ± 0.28 83.5 ± 2.70 392 ± 25
L  0 78.8 21.2 1 19.7 ± 0.15 118 ± 1.96 373 ± 36 25.1 ± 0.10 69.9 ± 1.76 339 ± 11
M 74.0  7.7 18.3 0.198 16.2 ± 0.11 131 ± 2.17 290 ±   2 20.9 ± 0.08 87.2 ± 0.70 373 ± 17
N  0 90.9  9.1 1 20.4 ± 0.47 125 ± 4.07 232 ± 20 23.4 ± 0.48 87.4 ± 1.83 276 ± 25
O 34.5 57.0  8.5 0.198 17.4 ± 0.29 133 ± 4.58 420 ±   9 21.4 ± 0.09 90.4 ± 1.33 561 ± 17
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Figure 62.   Experimentally obtained results (•) showing critical concentration of MS at 
0.198 and spline (dataNESIA/DesignNESIA) approximated data (—) at 0.206 
for renormalized MS concentrations regarding to the disintegration time of MA 
tablets compressed at 7 kN. 
 
6.7 Critical volume fraction of MS for MA tablets 
The percolation threshold of MS described by renormalized MS concentration; 
MS/(MS+MA) applying the renormalization technique was always equal 0.198 for 34.5 (% 
v/v), 55.1 (% v/v) and 74.1 (% v/v) MA tablet compressed at 7 kN and 5 kN. The critical 
volume fraction of MS (c,MS) for 34.5 (% v/v), 55.1 (% v/v) and 74.1 (% v/v) MA tablets 
compressed at 7 kN and 5 kN was within the range of 0.156-0.167 (v/v). It was calculated by 
Equation 30 from the basis of Equation 8 and compiled in Table 25 and 26. 
 
MSc, 198.0  Porosity1 of MA tablet                                                    Equation (30) 
 
In fact, Equation 30 corresponds to the case II of Equation 14 described below because the 
ratio of the radius of MS/MA (r/R) is 3.81 > 0.732. According to the percolation theory, a 
minimum disintegration time corresponds to the formation of a continuous water-conducting 
cluster through the entire tablet. In case II, porosity and disintegrant represent two 
independent water diffusion network. There are two possibilities for water to diffuse through 
the entire MA tablets: through a percolating cluster of pores or through an infinite cluster of 
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MS. However the dominant network that the water can diffuse for the disintegration of MA 
tablet is considered through the disintegrant network, not through the porous network 
according to the results of section 6.4. This situation that the particle size of inactive 
ingredient is bigger than that of API should be necessary for low water soluble drugs 
because they are normally milled in order to reduce the particle size and increase the 
dissolution rate. It is concluded that case II of Equation 14 is available not only for the binary 
tablets but also for the truly ternary pharmaceutical tablet formulation. Moreover the random 
close packed (RCP) system is also the best model for the pharmaceutical tablet formulation 
in case of spherical particles regardless the compressed particles are or powder or granules. 
 


 1
,disc
disX ;   if R
r
> 13      CaseII                                                            Equation (14) 
where Xdis is the critical concentration of disintegrant in powder mixture (v/v), c,dis is 0.16 
± 0.01 (v/v) and ε is the tablet porosity (v/v). 
 
Regarding to Tablet O, the dominant components in terms of volumetric percentage in the 
tablet is LA, not MA. The case I of Equation 14 has to be taken into account for calculating 
the critical concentration of MS because the ratio of the radius of MS/LA (r/R) is 0.635 ≤ 
0.732 which means the MS particles might be caged by LA. However the critical 
concentration of MS can be calculated by the case II of Equation 11. It might be considered 
that the ratio of the radius of MS/LA (r/R) being 0.635 is close to 0.732. The particle size of 
filler and disintegrant should be close to each other for the robust tablet formulation design. 
 
Table 25   Critical volume fraction of MS (c,MS) for MA tablets compressed at 7 kN 
 Composition (% v/v) 
 MA LA MS 
MS/(MS+MA) 
 
Porosity
(% v/v) 
Disintegration time 
(sec.) 
c,MS 
(v/v) 
F 55.1 31.3 13.6 0.198 15.8 266 0.167 
M 74.0  7.7 18.3 0.198 16.2 290 0.166 
O 34.5 57.0 8.5 0.198 17.4 420 0.164 
 
Table 26   Critical volume fraction of MS (c,MS) for MA tablets compressed at 5 kN 
 Composition (% v/v) 
 MA LA MS 
MS/(MS+MA) 
 
Porosity
(% v/v) 
Disintegration time 
(sec.) 
c,MS 
(v/v) 
F 55.1 31.3 13.6 0.198 20.5 418 0.157 
M 74.0  7.7 18.3 0.198 20.9 373 0.157 
O 34.5 57.0  8.5 0.198 21.4 561 0.156 
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6.8 Critical concentration of MS for 0% v/v MA tablets 
Tablet A, I, L and N were consisted of LA and MS without MA. Critical concentration of MS 
in these tablets compressed at 7 kN and 5 kN were calculated respectively in Table 27 and 
28 according to the case I of Equation 14 because the radius of MS/LA (r/R) is 0.635 ≤ 0.732. 
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 
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c
disX ;   if  13 R
r
    CaseI                                                   Equation (14) 
where Xdis is the critical concentration of disintegrant in powder mixture (v/v), c is 0.16 ± 
0.01 (v/v) and ε is the tablet porosity (v/v). 
 
Calculated critical concentration of MS for Tablet A, I, L and N compressed at 7 kN and 5 
kN was about 1% v/v (Table 27) and 0% v/v (Table 28). For this reason, the minimum 
disintegration time was found in a Tablet N which contained the lowest volume of MS in a 
tablet. However it is still unclear the effect of porosity of tablet on the critical concentration of 
MS when the porosity of tablet is more than 16% v/v for case I as this study. It is suggested 
that the porosity of tablet for case I should be much below 16% v/v from its hardness and 
robustness point of view because the porosity of tablet can be easily changed by tableting 
condition for example. 
 
Table 27   Critical concentration of MS in 0% v/v MA tablets compressed at 7 kN 
Composition (% v/v) 
 
MA LA MS 
Porosity
(% v/v) 
Disintegration time
(sec.) 
Xdis 
(% v/v) 
A 0 69.7 30.3 20.6 550 0% - 0.81% 
I 0 84.8 15.2 20.6 379 0% - 0.81% 
L 0 78.8 21.2 19.7 373 0% - 1.47% 
N 0 90.9  8.5 20.4 232 0% - 0.96% 
 
Table 28   Critical concentration of MS in 0% v/v MA tablets compressed at 5 kN 
Composition (% v/v) 
 
MA LA MS 
Porosity
(% v/v) 
Disintegration time
(sec.) 
Xdis 
(% v/v) 
A 0 69.7 30.3 25.4 517 0% 
I 0 84.8 15.2 24.5 312 0% 
L 0 78.8 21.2 25.1 339 0% 
N 0 90.9  8.5 23.4 276 0% 
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6.9 Comparison of critical volume fraction for MA tablets and Caffeine 
tablets 
For a close comparison with the results obtained in case of the MA tablets, we take into 
account so far unpublished results of the thesis of Luginbuehl [10]. 
Luginbuehl studied in his thesis the binary system of caffeine (anhydrous) - StaRX1500® at 
different size fractions. The binary mixtures were directly compressed by using the universal 
material tester Zwick 1478 (Zwick GmbH & Co). The exact procedure for the tableting 
process is described in the reference Luginbuehl and Leuenberger [10], where caffeine 
(anh.) granulate with an average particle size of 727 m was compressed with StaRX1500® 
(average particle size of 76 m). In this case, a critical concentration of StaRX1500® was 
found and interpreted as a percolation threshold pc = 0.071 (v/v). On the other hand, the 
caffeine (anh.) granulate with an average particle size of 47 m was compressed with 
StaRX1500® (average particle size of 76 m). In this case, a critical concentration of 
StaRX1500® was found and interpreted as a percolation threshold pc = 0.194 (v/v). Critical 
volume fraction (c) was calculated by Equation 14 and compiled in Table 29. Critical volume 
fractions (c) for both cases were also within the range of 0.16 ± 0.01 (v/v). 
 
Table 29   Critical volume faction depending on the case 
Average particle size (m) 
StaRX1500® 
Caffeine 
(anh.) 
Case 
(r/R) 
Critical concentration of 
StaRX1500® (v/v) 
Porosity 
(% v/v) 
c 
(v/v) 
76 727 I (0.10) 0.071 12 ± 0.2 0.168 
76 47 II (1.62) 0.194 12 ± 0.2 0.170 
 
The following data [10] refer to a caffeine (anh.) powder with the average particle size of 47 
m which was compressed together with StaRX1500® having the average particle size of 76 
m (case II). The present investigation was done in the range ca. 0.1-0.4 volume of 
StaRX1500® in the vicinity of a percolation threshold. In Figure 63, the critical concentration 
of StaRX1500® was calculated using the spline function with the dataNESIA software. It was 
leading to very close to 0.195 (v/v). It is important to mention here that the solubility of API 
does not affect the location of critical concentration of non-fibrous disintegrant. 
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Figure 63.   Experimentally obtained results (•) showing critical concentration of 
StaRX1500® at 0.194 (v/v) and spline (dataNESIA/DesignNESIA) 
approximated data (—) at 0.195 (v/v) regarding to the disintegration time of 
caffeine tablets for case II. 
 
6.10 Critical exponent for disintegration behavior 
In this study the percolation thresholds pc describe the location of the minimum value of the 
disintegration time. These pc-values were kept constant for the further evaluation of Equation 
15. For the determination of the critical exponent q of Equation 15, a non-linear curve fitting 
method was applied by using the Levenberg-Marquardt [124] algorithm for both spline 
approximated and raw datasets of MA tablets compressed at 7 kN (Figure 64) and caffeine 
tablets (Figure 65) for case II (critical exponent of caffeine tablets for disintegration behavior 
in case I was reported as 0.30 ± 0.05 [10]). Equation 15 includes the percolation threshold pc 
as an important parameter describing the microstructure and critical concentration of the 
disintegrant. The second parameter is the critical exponent q which depends, in general, on 
the system property related to the probability (p) of cluster [71], in other word on nature of the 
(disintegration) process [97]. Critical exponent for binary (caffeine tablets) and 
multicomponent tablets (MA tablets) with non-fibrous types of disintegrant (StaRX1500® and 
MS) are 0.30 and 0.28 very close to each other (average values are: q = 0.28 ± 0.06, see 
Table 30). 
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Figure 64.   Results of fitting Equation 15 for MA tablets compressed at 7 kN; figure shows 
fitting (—) with spline approximated data (dotted line) and raw experimental 
data (•). 
 
0.1 0.15 0.2 0.25 0.3 0.35 0.4
StaRX1500 ®,Hv･vL20
30
40
50
60
70
T
tnised
.Hces.L SEC.
V
•
•
•
•
•
•
•
•
•
•
••
•
•
•
 
Figure 65.   Results of fitting Equation 15 for caffeine tablets for case II, fitting (—) with 
spline approximated data (dotted line) and raw experimental data (•). 
Results and Discussion 
108 
Table 30   Critical exponent and goodness of fit 
Data type q r2 
MA 7kN raw data 0.28 0.91 
MA 7kN spline approximated data 0.35 0.77 
MA 5kN raw data 0.23 0.92 
MA 5kN spline approximated data 0.19 0.84 
Caffeine raw data 0.30 0.78 
Caffeine spline approximated data 0.33 0.79 
Average values ± standard deviation 0.28 ± 0.06 0.84 
 
The behavior of the disintegration time in the neighbourhood of the percolation threshold 
can be mathematically explained with the basic equation of the percolation theory (Equation 
15) yielding a critical exponent q was equal to 0.28 ± 0.06 (The quality of fit: r2 = 0.84). 
Please note that with one exception, the quality of fit, i.e. the r2 values are significantly better 
in case of using the raw data and not the approximated (smoothened) data achieved with the 
dataNESIA method. The average value in Table 30 is close to 0.3, has the same magnitude 
as β (see Table 10), but is different from 0.4. In the context of the publication of Luginbuehl 
and Leuenberger [9] the critical exponent indicates that the presence and the strength of 
infinite cluster for its concentration above the percolation threshold plays a role. It is 
suggested that the disintegration behavior is related to the strength of disintegrant cluster [9, 
71]. Disintegration time decreases with increasing the disintegrant volumetric percentage (% 
v/v) of the mixture until percolation threshold. After this percolation threshold of disintegrant, 
disintegration time increases again with increasing disintegrant volumetric percentage. The 
excess of disintegrant particles in fact makes disintegration time slower due to the swelling of 
the excess amount of disintegrant, which slows down the entrance of water by the diffusion 
process. Thus the critical exponent of disintegration behavior is considered lower than 0.4 [9]. 
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6.11 Computing the disintegration time of MA tablet by F-CAD 
There are mainly two software to simulate the dissolution profile either F-CAD (algorithm is 
cellular automata) or DDDPlusTM from Simulation Plus, Inc. (algorithm is mathematical 
modeling) [125]. DDDPlusTM is commercially available for the pharmaceutical industry. 
However, so far, there does not exist a specific software to simulate the disintegration time of 
a solid dosage form as a function of its formulation. In this work, Dissolution simulation (DS) 
module, which is the one of F-CAD is used to get an estimate of the disintegration time of a 
MA tablet. It is assumed that the “time elapsed” till water is detected at the geometric center 
of the virtual tablet is proportional to the disintegration time. The “time elapsed” happens 
before the disintegration of the tablet is completed .It has to be kept in mind that F-CAD 's 
core module being based on the cellular automata is following a "first principle" approach 
(see Figure 7) [62, 94, 96, 100]. 
6.11.1 Particle Arrangement and Compaction (PAC) operation 
According to Table 11, the mean diameter of MA, LA and MS was 6.57, 39.4, 25.0 m, 
respectively. LA and MS particles are six times and four times bigger than MA. Thus the 
growth function was used for arranging the LA and MS particles into the tablet created by TD 
module until LA and MS were grown to ca. 550 m and 350 m respectively, because the 
distributed MA particle size was 96.15 m/cube side. In order to simulate LA granules were 
arranged into the virtual tablet, LA was once removed and grown again to follow the ‘Swiss 
cheese’ procedure [100]. Because it is assumed that granulated particle should be grown at 
limited location in a tablet as competed with direct compressive tablet of powder mixture. 
According to the appearance of granules by SEM in Figure 50b, 50c and 50d, it was 
observed that MA and MS particles were granulated around LA particles. Thus MA and MS 
particles were removed and distributed again after LA was grown in order to simulate 
granules observed by SEM. 
6.11.2 Comparison of experimental and F-CAD computed disintegration time of MA 
tablets 
Comparison of experimental disintegration time of tablets compressed at 7 kN and 
computed specific time point for water to reach the geometric center of the tablet by F-CAD 
software has been carried out. Experimental disintegration time and computed specific time 
point for water to reach the geometric center of the virtual tablet are shown in Table 31 and 
Figure 66. If all data in Figure 67 (including Tablet K and M) are submitted to a linear 
regression analysis, no correlation can be found (r2 = 0.0154). However, if the Tablets K and 
M are not taken into consideration, ca. 66% (r2 = 0.6564) of the data can be explained with a 
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linear regression, yielding a correlation coefficient of r = 0.81 (Figure 68), however this is 
much less than expected from the excellent results of F-CAD to simulate the dissolution 
profile of many different formulations [12, 94, 96, 100]. The reason that it was difficult to 
compute the disintegration time of Tablet K and M by F-CAD might be related to the fact that 
the loading volume of MS was higher than that of LA (see Table 31). In other word, MS 
particles were nice to be grown instead of LA. According to the percolation theory, a 
minimum disintegration time corresponds to the formation of a continuous water-conducting 
cluster through the entire tablet. When the MS particle was grown for Tablet M instead of LA, 
the disintegration time of Tablet M by F-CAD was 116 ± 9 (n=6) sec., which was much closer 
to the experimental disintegration time. The way of disintegrant particle arrangement in the 
virtual tablet has to be taken into account in order to compute the disintegration time of tablet 
by F-CAD if the disintegrant was granulated as a tableting granules as a further investigation. 
 
Table 31   Experimental disintegration time of tablets compressed at 7 kN and computed 
specific time point for water to reach the geometric center of the tablet by using 
F-CAD 
 Composition (% v/v) Disintegration time (sec.) 
 
MA LA MS 
MS/(MS+MA) 
Experimental data 
(n=3) 
F-CAD data 
(n=6) 
B 12.0 61.4 26.6 0.698 596 ±   8 338 ± 10 
C 23.5 53.4 23.1 0.497 616 ±   6 408 ±   7 
D 34.5 45.7 19.8 0.365 604 ± 21 448 ± 14 
E 45.0 38.4 16.6 0.27 428 ± 16 395 ± 14 
F 55.1 31.3 13.6 0.198 266 ±   8 191 ± 13 
G 64.8 24.6 10.6 0.141 453 ± 24 432 ± 19 
H 74.1 18.1   7.8 0.096 758 ± 15 785 ± 24 
J 34.5 51.3 14.2 0.292 535 ± 12 382 ± 10 
K 74.1 12.9 13.0 0.15 413 ±   8 596 ±   9 
M 74.0   7.7 18.3 0.198 290 ±   2 897 ±   8 
O 34.5 57.0 8.5 0.198 420 ±   9 350 ± 13 
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Figure 66.   Comparison of experimental disintegration time of tablets compressed at 7 kN 
(black bar) and computed specific time point for water to reach the geometric 
center of the tablet by F-CAD (white bar). 
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Figure 67.   The relationship of the experimental disintegration times and F-CAD computed 
specific time points for water to reach the geometric center of the virtual tablet. 
Please note that no significant linear regression can be calculated, if the 
results of Tablet K and M are included (r2 = 0.0154). 
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Figure 68.   The relationship of the experimental disintegration time and F-CAD computed 
specific time point for water to reach the geometric center of the virtual tablet 
in case, that Tablet K and M were excluded (r2 = 0.66, r = 0.81). 
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6.11.3 Response surfaces close to the percolation threshold of sensitive tablet 
properties such as the disintegration time 
Figure 69 shows the typical behavior for a percolation effect. The percolation threshold of 
MS expressed by renormalized MS concentration with respect to the minimum F-CAD 
disintegration time was observed at 0.198. 
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Figure 69.   Experimental disintegration time (●) and F-CAD values (△) as a function of the 
renormalized MS concentration. Please note that the Tablets: E, F, G, J, K, M, 
and O show close to the percolation threshold of MS, a similar behavior for the 
values of the experimental disintegration time and for the F-CAD calculated 
values. 
 
It is important to realize that F-CAD is capable of detecting this percolation threshold 
(Figure 69). Due to the fact, that F-CAD can be applied without performing any laboratory 
experiment, it has been decided to explore with F-CAD the behavior of the F-CAD calculated 
disintegration time in the very close neighborhood of the percolation threshold. Such an 
exploration is difficult and cost intensive to perform in a laboratory but can be done without 
major problems in-silico. For this reason, two additional in-silico experiments followed by the 
central composite design (CCD) with two factors, i.e. MS (% v/v) and the ratio of LA/MA 
corresponding to the ratio of hydrophilic excipient/hydrophobic drug substance, have been 
performed, which are described below in Table 32 and 33. The response surfaces (Figure 70 
Results and Discussion 
114 
and 71) were described by a software of Design-Expert 7®. Interestingly, the percolation 
effect of disintegration time of tablet computed by F-CAD was clearly observed (Figure 70) 
near the Trial No. 1 in Table 32 (= Tablet F, see Table 31) which had the absolute minimum 
disintegration time by experimental results. On the other hand, the percolation effect was not 
observed near the Trial No. 14 in Table 33 (= Tablet M, see Table 31) where is the high 
loading volume of MA, more than 64.8% v/v as shown in Figure 71.  
 
Table 32   First additional in-silico experiments (CCD 1) computed the specific time point for 
water to reach the geometric center of the tablet by using F-CAD 
Composition (% v/v) Disintegration time (sec.)Trial 
No. MA LA MS 
LA/MA MS/(MS+MA)
F-CAD data (n=4) 
1 55.1 31.3 13.6 0.568 0.198   199 ± 20 
2 45.0 44.4 10.6 0.987 0.191   290 ±   7 
3 64.8 24.6 10.6 0.380 0.141   438 ± 10 
4 64.8 18.6 16.6 0.287 0.204 1126 ± 14 
5 45.0 38.4 16.6 0.853 0.269   395 ±   9 
6 45.0 41.4 13.6 0.420 0.232   374 ±   9 
7 64.8 21.6 13.6 0.333 0.173   574 ± 24 
8 55.1 34.3 10.6 0.623 0.161   422 ± 13 
9 55.1 28.3 16.6 0.514 0.232   467 ± 16 
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Figure 70.   Response surface of the computed F-CAD disintegration time (TDis, sec.) from 
the first additional in-silico experiments (CCD 1, Table 32). 
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Table 33   Second additional in-silico experiments (CCD 2) computed the specific time point 
for water to reach the geometric center of the tablet by using F-CAD 
Composition (% v/v) Disintegration time (sec.)Trial 
No. MA LA MS 
LA/MA MS/(MS+MA)
F-CAD data (n=4) 
10 72.4 12.3 15.3 0.170 0.174   668 ± 21 
11 79.4 8.3 12.3 0.104 0.134 1070 ± 21 
12 70.7 17.0 12.3 0.240 0.148 1103 ± 70 
13 65.9 15.8 18.3 0.240 0.217 1232 ±  20 
14 74.0 7.7 18.3 0.104 0.198   896 ± 22 
15 76.7 8.0 15.3 0.104 0.166 1133 ± 23 
16 68.3 16.4 15.3 0.240 0.183 1143 ± 31 
17 75.0 12.7 12.3 0.170 0.141   777 ± 16 
18 69.8 11.9 18.3 0.170 0.208 1726 ± 46 
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Figure 71.   Response surface of the computed F-CAD disintegration time (TDis, sec.) from 
the second additional in-silico experiments (CCD 2, Table 33). 
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The need to eliminate Tablet M and Tablet K results show clearly that there is a necessity 
for further investigations and for an improvement of the method to calculate the F-CAD 
disintegration time. In fact, it has to be questioned, whether the F-CAD disintegration time is 
the right surrogate to simulate the experimental disintegration time. The very rigorous PhD 
study of Luginbuehl [10] with the main scientific findings published in 1994 [9] show as 
results the behavior of the water uptake constant K. The disintegration time tdis and the 
intrinsic dissolution rate of the active substance close to the percolation threshold. 
Interestingly, neither the percolation thresholds pci nor the corresponding critical exponents qi 
were identical for the three different properties i of the tablet. However, it can be noted that 
the parameters pci and qi are different, but close to each other. It may be possible that the F-
CAD disintegration time, which simulates the “time elapsed” till the water molecules reach 
the center of the tablet, should be better compared with the “water uptake” constant K as 
described in the study of Luginbuehl [9]. However, as already stated in the study of 
Luginbuehl [9] one cannot expect to find identical percolation thresholds and in addition 
especially not identical critical exponents for different properties of the compact. F-CAD 
software is the only software so far, which is capable of computing the disintegration time of 
tablets. The software has a great potential to be further improved and to be not only used for 
the safe prediction of the dissolution profile of a tablet formulation but also for a safe 
prediction of the disintegration time. However, it has to be kept in mind that such an 
application of F-CAD is only possible, if there is the awareness, that for a safe exploration of 
the design space according to ICH Q8 it is a prerequisite to take into account the effect of 
percolation theory. This means in practice that the exploration of the design space needs to 
be done with the appropriate resolution, i.e. the “mesh size” of the lattice points to be 
investigated in the design space needs to be fine enough. In addition close to the percolation 
threshold, it is necessary to apply the basic equation of the percolation theory, i.e. the power 
law, with the parameters pc and q, (percolation threshold and critical exponent). It is not 
sufficient to use a simple 2n design or a central composite design as both type of designs 
yield as a “summarizing equation” by a first or second orders approximation of the reality. 
Thus, “Dangerous canyon” close to the percolation threshold leading to a high variability of a 
sensitive tablet property may not be detected by only response surface methodologies. The 
difference in the resolution of the exploration of the design space becomes visible by 
comparing Figure 70 and Figure 71. Both response surfaces are the result of a CCD (central 
composite design) with different a “mesh size” of the lattice points in the design space 
explored. The minimum in Figure 70 is more prominent than in Figure 71. 
It is evident that such a design space exploration with classical laboratory experiments is 
extremely difficult to realize and would be extremely expensive. In this respect, the 
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application of F-CAD opens a new research avenue, i.e. a “new kind of science” in the 
language of Stephan Wolfram (Princeton University) [103]. 
The results of this thesis show that the application of percolation theory is a must in order to 
detect percolation thresholds. It is important to know the response surfaces close to the 
percolation threshold of sensitive tablet properties such as the disintegration time to get 
information about the robustness of the selected formulation. In this context one has to put 
the question forward if the application of percolation theory and the use of F-CAD to detect 
the percolation thresholds should be an integral part of the guidelines of ICH Q8 exploring 
the formulation design space. 
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7 Conclusions 
The present study shows among others that the application of percolation theory is not 
limited to typical and formal binary tablet formulations. The critical concentration of maize 
starch (MS) for the truly ternary pharmaceutical mefenamic acid (MA) tablet formulations, 
has been described by the renormalized MS concentration; MS/(MS+MA) applying the 
renormalization technique. The following result is obtained for the critical concentration in 
terms of the renormalized dimensionless concentration: 0.198. 
In case dataNESIA software is applied, there is the advantage that the data of a response 
surface analysis can be smoothed by interpolation of the measured data with a spline 
function. It leads to a minimum disintegration time at 0.206, which is very close to 0.198. 
According to the percolation theory, a minimum disintegration time corresponds to the 
formation of a continuous water-conducting cluster through the entire tablet. The critical 
volume fraction of cluster that water can diffuse through the entire MA tablets are calculated 
with taking into account the geometrical considerations between MS and MA particles based 
on random close packed (RCP) spheres system. The critical volume fraction of MS is 
calculated by the multiplication of critical concentration of MS and the solid fraction of MA 
tablets; which is within the range of 0.16 ± 0.01 (v/v). It is concluded that the critical volume 
fraction for three dimensional lattices is equal to 0.16 ± 0.01 (v/v); which is useful for the 
calculation of the critical concentration of starch based disintegrant in order to design the 
pharmaceutical tablet formulation based on scientific approach proposed by ICH Q8 
guidance. 
In addition, the disintegration behavior in the neighborhood of the percolation threshold is 
explained mathematically by the basic equation of the percolation theory, yielding a critical 
exponent q equal to 0.28 ± 0.06 (Quality of fit: r2 = 0.84). This value is close to the critical 
exponent for three dimensional lattices (q = 0.4); which indicates the strength of infinite 
cluster for its concentration above the percolation threshold.  
The comparison of these results between MA tablets and caffeine tablets lead to very 
similar values for the critical concentration of non-fibrous disintegrant and critical exponent 
for disintegration behavior. These results can lead to the following conclusions: 
1. The solubility of the drug substance does not affect the location of critical 
concentration of non-fibrous disintegrant and critical exponent for disintegration 
behavior. 
2. The critical exponent q is close to q ≈ 0.3 for the disintegration behavior of 
pharmaceutical tablets. 
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From the point of view to choose the best the experimental design to find the critical 
concentration of the disintegrant, it is highly recommended to take into account the 
percolation theory. Thus, among others, the experimental range can be narrowed. However it 
has to be kept in mind that the determination of the percolation threshold and critical 
exponent does not give an answer about the absolute value of the disintegration time. 
Due to the steadily rising costs for developing and finally for registering a new drug 
substance, the pharmaceutical industry starts to use for a rapid pharmaceutical development 
more and more software tools. Such an approach is not new and has been successfully 
introduced in the automotive industry with Toyota as a pioneer using the principle of “Quality 
by Design” [126]. Today, not only cars but also aircrafts such as the Boeing 777 and the 
Airbus 380 are first constructed and tested in-silico. Such an approach is considered as best 
practice. In the present study the software F-CAD (Formulation-Computer Aided design) [95] 
is used to calculate in-silico the expected time of disintegration. F-CAD has been very 
successfully applied so far to predict the dissolution profile of a tablet [94, 96, 100] and there 
is a conjecture, that the “time elapsed” till water molecules reach the center of the tablet, 
which can be calculated by F-CAD could be a surrogate for the effectively measured 
disintegration time. Thus, the Dissolution Simulation (DS) module of F-CAD, which is based 
on cellular automata algorithm has been used to simulate the disintegration time of a MA 
tablet. In the present study, the experimental disintegration time of tablet is compared with 
the calculated specific time point for water to reach the geometric center of the tablet. In 
general, there is not a specific problem to calculate these specific times. However, the Tablet 
K and M show difficulties to compute the F-CAD disintegration time. Interestingly, if these two 
Tablets are not taken into account, a correlation between the real disintegration time and the 
F-CAD estimate a correlation between the two tablet formulation properties could be 
obtained with a correlation coefficient: r = 0.81. Compared to the much better achievements 
of F-CAD by calculating the dissolution profile of a tablet formulation, it become evident that 
there is a need for further studies and an improvement of F-CAD. It has to be noted, on the 
other hand, that there is so far no other software available, which is able to predict the 
disintegration time. The disintegration is the key property, especially for low water soluble 
drugs. Often the disintegration test can reduce the number of dissolution runs for the design 
and process development of immediate release tablet formulation at the early stage such as 
phase I and II before POC study [127]. 
It is concluded that F-CAD software is one of the tools for the substitution of laboratory 
experiments for the purpose of the design and development of new pharmaceutical solid 
dosage forms. The replacement of expensive laboratory experiments by in-silico experiments 
is an important issue to reduce development costs and to comply with the requirements of 
ICH Q8 exploring the design space with response surface methodology. The results of this 
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thesis show in addition, that the application of percolation theory is a must in order to detect 
percolation thresholds. It is important to know the response surfaces close to the percolation 
threshold of sensitive tablet properties such as the disintegration time to get information 
about the robustness of the selected formulation. In this context one has to put the question 
forward if the application of percolation theory should be an integral part of the guidelines of 
ICH Q8 exploring the formulation design space. 
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8 Further perspectives 
In our laboratory, the critical concentration of fibrous disintegrant was found at about 3% v/v 
in a binary compact consisting of caffeine or indomethacin and Ac-Di-Sol® [12]. Fibrous 
disintegrant is also used for intra-granular excipient in a pharmaceutical tablet. It is important 
to know the effect of wet granulation on the critical concentration of fibrous disintegrant. 
Moreover it is also important to investigate the critical concentration of disintegrant if it is 
used for extra-granular excipient in order to establish the rule of pharmaceutical tablet 
formulation design. 
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